var title_f32_12_32960="Echogenic bowel1";
var content_f32_12_32960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echogenic bowel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of pelvis in fetus at 18 weeks gestational age shows echogenic bowel. The bowel is as bright as the iliac wing on the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32960=[""].join("\n");
var outline_f32_12_32960=null;
var title_f32_12_32961="RBC dysplasia in MDS";
var content_f32_12_32961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Red blood cell dysplasia in myelodysplastic syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dysplastic nucleated red blood cells, peripheral blood. Abnormal nuclear shape (black arrow) and basophilic stippling (red arrow) are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Farhi DC. Myelodysplastic syndromes. In: Pathology of Bone Marrow and Blood Cells, 2nd ed, Farhi DC (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32961=[""].join("\n");
var outline_f32_12_32961=null;
var title_f32_12_32962="Distal femoral metaphyseal fracture in a child";
var content_f32_12_32962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal femoral metaphyseal (supracondylar) fracture in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 582px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) This 6-year-old patient sustained an unstable supracondylar fracture of the femur.",
"    <br/>",
"    (B) The fracture was managed with immediate spica casting with the knee in 90 degrees of flexion, mandatory in such a case to prevent posterior angulation.",
"    <br/>",
"    (C) Bayonet apposition is acceptable in a child this age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Flynn JM, Skaggs DL. Femoral shaft fractures. In: Beaty JH, Kasser JR. Rockwood and Wilkins' Fractures in Children, 7th edition, Lippincott Williams &amp; Wilkins, Philadelphia, 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32962=[""].join("\n");
var outline_f32_12_32962=null;
var title_f32_12_32963="Parapsoriasis large plaque";
var content_f32_12_32963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large plaque parapsoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous patches with minimal scale that are several centimeters in diameter are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32963=[""].join("\n");
var outline_f32_12_32963=null;
var title_f32_12_32964="Disseminated candidiasis skin";
var content_f32_12_32964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55977%7EID%2F75717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55977%7EID%2F75717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin lesions of disseminated candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tiny pustular lesions due to the hematogenous dissemination of",
"    <em>",
"     Candida albicans",
"    </em>",
"    can be seen in this hospitalized patient with fever and signs of sepsis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol A Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodules in disseminated candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large erythematous, nodular lesions with central necrosis in a patient with acute leukemia and disseminated candidiasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Jones, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32964=[""].join("\n");
var outline_f32_12_32964=null;
var title_f32_12_32965="Stavudine: Patient drug information";
var content_f32_12_32965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Stavudine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     see \"Stavudine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/9/33942?source=see_link\">",
"     see \"Stavudine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zerit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zerit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause irritation to the pancreas, liver problems, or change acid levels in the blood. Closely read the part in this leaflet which lists when to call your doctor. If you are pregnant, you may have more chance of having high acid levels when taking stavudine and didanosine at the same time. Only use these 2 drugs at the same time when the good effects outweigh the bad effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to stavudine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698527",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant and taking didanosine and stavudine, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698278",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nerve problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pancreatitis may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (solution) in a refrigerator. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11054 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-2BDF7BB03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32965=[""].join("\n");
var outline_f32_12_32965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223021\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223022\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028300\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028302\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028301\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028306\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028307\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028309\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028304\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028305\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028310\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028311\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=related_link\">",
"      Stavudine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/9/33942?source=related_link\">",
"      Stavudine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_12_32966="Major side effects and safety of calcium channel blockers";
var content_f32_12_32966=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Major side effects and safety of calcium channel blockers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/12/32966/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/12/32966/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/12/32966/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/12/32966/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/12/32966/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/12/32966/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/12/32966/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers are widely used in the treatment of hypertension, angina pectoris, cardiac arrhythmias, and other disorders, and the longer-acting preparations have been prescribed with increasing frequency. A review of the major side effects associated with these agents and the previous controversy concerning their effect on coronary events, mortality, gastrointestinal bleeding, and the development of cancer is presented here. The management of calcium channel intoxication is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31736?source=see_link\">",
"     \"Calcium channel blocker poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF CALCIUM CHANNEL BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While all calcium channel blockers inhibit the L-type calcium channel on cells, they are divided into two major categories based upon their predominant physiologic effects: the dihydropyridines, which are predominantly vasodilator and generally have neutral or increased effects on vascular permeability; and the non-dihydropyridines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , which reduce vascular permeability and affect cardiac contractility and conduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dihydropyridines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dihydropyridines are potent vasodilators that have little or no negative effect upon cardiac contractility or conduction. They can be further divided into three categories based upon half-life and effect on contractility:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Short-acting (capsule containing liquid)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"     </li>",
"     <li>",
"      Longer-acting formulations with little cardiac depressant activity &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/45/2775?source=see_link\">",
"       felodipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/56/903?source=see_link\">",
"       isradipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      GITS and CC, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22295?source=see_link\">",
"       nisoldipine",
"      </a>",
"     </li>",
"     <li>",
"      Long-acting agents with no cardiac depressant activity &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      , lacidipine",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Non-dihydropyridines",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    and, to a lesser extent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    are somewhat less potent vasodilators, but they have a greater depressive effect on cardiac conduction and contractility compared to dihydropyridines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/57/39831?source=see_link\">",
"     \"Calcium channel blockers in the treatment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     KNOWN SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects that may be seen with calcium channel blockers vary with the agent that is used. The potent vasodilators can, in 10 to 20 percent of patients, lead to one or more of the following: headache, dizziness or lightheadedness, flushing, and peripheral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/2\">",
"     2",
"    </a>",
"    ]. The major adverse effect with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    is constipation, occurring in over 25 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral edema associated with calcium channel blockers, which is less frequent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , is related to redistribution of fluid from the vascular space into the interstitium, possibly induced by vasodilation, which allows more of the systemic pressure to be transmitted to the capillary circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/4\">",
"     4",
"    </a>",
"    ]. In one study of 12 healthy subjects, for example, a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    increased the foot volume despite also increasing sodium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, treatment of this form of edema with a diuretic may not relieve the edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, edema is much less common when a dihydropyridine is given with an inhibitor of the renin-angiotensin system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This effect is probably related to venodilation by the ACE inhibitor, which helps remove the fluid sequestered in the capillary bed by the arteriolar dilation from the calcium channel blocker.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Effects on cardiac function",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    and, to a lesser degree,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    can diminish cardiac contractility and slow cardiac conduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, these drugs are relatively contraindicated in patients who are taking beta blockers or who have severe left ventricular systolic dysfunction, sick sinus syndrome, and second or third degree atrioventricular block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Use in heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns over the negative inotropic effects of the calcium channel blockers and increased sympathetic activity induced by the short-acting dihydropyridines have restricted the use of these agents in the treatment of patients with heart failure due to impaired systolic function. However, the long-acting dihydropyridines (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    ) appear to be safe when given for angina or hypertension to patients with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30438?source=see_link\">",
"     \"Calcium channel blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SERIOUS ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns have been raised about the possible long-term safety of therapy with calcium channel blockers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Increased mortality after acute MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large doses of short-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    may increase mortality in patients in the immediate post-myocardial infarction period (",
"    <a class=\"graphic graphic_figure graphicRef76385 \" href=\"mobipreview.htm?17/14/17645\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/9\">",
"     9",
"    </a>",
"    ]. The potential for harm from the profound hypotension and sympathetic activation induced by such large doses of short-acting nifedipine is incontrovertible in these hemodynamically vulnerable patients (",
"    <a class=\"graphic graphic_table graphicRef52312 \" href=\"mobipreview.htm?15/33/15899\">",
"     table 1",
"    </a>",
"    ). Thus, there is no compelling reason to use short-acting calcium channel blockers in such patients.",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    in post-MI patients, and the effects of calcium channel blockers in patients with heart failure due to systolic dysfunction, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40469?source=see_link\">",
"     \"Calcium channel blockers in the management of acute coronary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30438?source=see_link\">",
"     \"Calcium channel blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Increased risk for acute MI in hypertensive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A highly publicized 1995 report suggested that calcium channel blockers increased the risk for an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/10\">",
"     10",
"    </a>",
"    ]. This case-control study compared 623 hypertensive patients who had had a myocardial infarction to 2032 patients who had not. Patients treated with a short-acting calcium channel blocker (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) had a relative risk of 1.6 for myocardial infarction, a finding that was not seen with diuretics, beta blockers, or angiotensin converting enzyme inhibitors. The relative risk increased (2.88 to 3.33) only in patients treated with high doses; the risk with low doses of a calcium channel blocker was similar to that seen with other antihypertensive drugs. \"High\" and \"low\" referred to daily doses greater than or less than 30 mg of nifedipine, 180 mg of diltiazem, and 240 mg of verapamil (",
"    <a class=\"graphic graphic_figure graphicRef51222 \" href=\"mobipreview.htm?28/33/29213\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These provocative observational findings are, by nature, uncontrolled and inconclusive. Many confounding variables could be responsible, and two are of particular concern: patient selection and the use of short-acting calcium channel blockers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihypertensive therapy was selected by the patients' clinicians. Therefore, it is probable that patients receiving a calcium channel blocker had more underlying coronary disease. The likelihood that such confounding was largely responsible for the apparent increase in myocardial infarctions was supported in an analysis of 77,196 patients given antihypertensive therapy between 1990 and 1992 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/11\">",
"     11",
"    </a>",
"    ]. Those started on a calcium channel blocker were 7.8 times more likely to have arteriosclerotic coronary disease, 2.9 times more likely to have angina, and 1.5 times more likely to have diabetes than those given other antihypertensive drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Short- versus long-acting calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium channel blockers evaluated in the above trials were short-acting preparations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    . Multiple randomized controlled trials involving thousands of hypertensive patients have found no evidence of increased coronary risk from long-acting calcium channel blockers which, as noted above, do not share the possible harmful cardiovascular effects of the short-acting preparations (",
"    <a class=\"graphic graphic_table graphicRef52312 \" href=\"mobipreview.htm?15/33/15899\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. These trials are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Increased mortality, gastrointestinal bleeding, and cancer in the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four studies from the same investigators reported the mortality and morbidity of approximately 1000 hypertensive patients among a total of 8000 elderly individuals screened as part of a three-community epidemiologic study. Among the hypertensive patients, approximately 200 individuals (20 percent) were taking calcium channel blockers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first study reported an increased mortality rate for patients in whom a short-acting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      was being administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second described an increased rate of gastrointestinal hemorrhage in those taking short-acting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , but not",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The third described an increase in various cancers in those taking short-acting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      , but not",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The fourth evaluated the incidence of cancer among a larger portion of the same population, including 450 subjects who were taking calcium channel blockers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/19\">",
"       19",
"      </a>",
"      ]. A multivariate analysis of possible confounding variables was used to compare the two nonrandomized populations. The following results were obtained:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An increased hazard ratio of 1.72 for developing cancer was found for patients taking calcium channel blockers",
"     </li>",
"     <li>",
"      The increased risk for cancer was dose-dependent and found for a variety of different types of cancers",
"     </li>",
"     <li>",
"      No increased risk was uncovered among those taking cardiovascular medications other than a calcium channel blocker",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These cohort studies on the same population of elderly people (average age 78, range from 71 to 96) have multiple potential faults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In all four studies, no attempt was made to determine whether patients who were reportedly taking calcium channel blockers at the one survey point in 1988 had actually continued to take these drugs. As a result, a patient considered among those who were taking a calcium channel blocker may have only received the drug for one day or not at all.",
"     </li>",
"     <li>",
"      The total number of reported adverse effects was small since only a few patients were taking different antihypertensive drugs.",
"     </li>",
"     <li>",
"      The much larger population (over 4000 patients) not taking a beta blocker, ACE inhibitor, or calcium channel blocker were excluded. About one-half of these patients were taking a diuretic.",
"     </li>",
"     <li>",
"      Patients on calcium channel blockers were more likely to be hospitalized since those given calcium channel blockers were in poorer health than those not receiving these drugs. As a result, the presence of gastrointestinal hemorrhage or cancer was more likely to be uncovered. As noted earlier, such confounding by indication is the likely reason for these observational data [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the multiple problems inherent in uncontrolled, retrospective case-control and cohort observational studies, conclusions drawn from these reports are frequently found to be in error after controlled, prospective, randomized studies are performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/20\">",
"     20",
"    </a>",
"    ]. Furthermore, the authors of these papers have extended the putative associations found from the use of short-acting calcium channel blockers to that of long-acting formulations.",
"   </p>",
"   <p>",
"    This conclusion is not warranted since the two groups of calcium channel blockers greatly differ in their effects (",
"    <a class=\"graphic graphic_table graphicRef52312 \" href=\"mobipreview.htm?15/33/15899\">",
"     table 1",
"    </a>",
"    ). Moreover, in a complete analysis of all the proposed hazards of calcium channel blockers, Kizer and Kimmel conclude the following: \"Initial reports of cancer, bleeding, and suicide have been contradicted by subsequent data, making the association uncertain or unlikely\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=see_link\">",
"       \"Patient information: Dealing with side effects from medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, these studies point out the potential risk of short-acting calcium channel blockers. However, a number of additional published trials show no increased risk from the longer-acting calcium channel blockers in patients who are post myocardial infarction or who have heart failure or hypertension.",
"   </p>",
"   <p>",
"    As a result, a prudent recommendation is that the use of short-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    be curtailed. In addition to the apparent increase in long-term risk with short-acting calcium channel blockers, the acute use of sublingual nifedipine in patients with severe hypertension can also be detrimental, possibly inducing hypotension, which can lead to cerebrovascular or coronary ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28246?source=see_link\">",
"     \"Management of severe asymptomatic hypertension (hypertensive urgencies)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is our feeling, and the opinion of most experts who have reviewed the evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/20,23\">",
"     20,23",
"    </a>",
"    ], that the above findings should not deter clinicians or patients from using long-acting calcium channel blockers for the treatment of hypertension and angina when they are clearly indicated. Indications include elderly patients with isolated systolic hypertension and patients with one of the following coexisting conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angina pectoris",
"     </li>",
"     <li>",
"      Raynaud phenomenon",
"     </li>",
"     <li>",
"      Asthma or chronic obstructive pulmonary disease",
"     </li>",
"     <li>",
"      Failure to respond to or tolerate other medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CCBs are widely used as second and third agents. Long-acting dihydropyridines are usually chosen, but non-DHP CCBs may reduce proteinuria more than DHPs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32966/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be appreciated, however, that there is usually no compelling reason to use a calcium channel blocker as a first-line agent in the treatment of most patients with essential hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/1\">",
"      Triggle DJ. Drug targets in the voltage-gated calcium channel family: why some are and some are not. Assay Drug Dev Technol 2003; 1:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/2\">",
"      Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens 2001; 15:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/3\">",
"      Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/4\">",
"      Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens 2011; 29:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/5\">",
"      van Hamersvelt HW, Kloke HJ, de Jong DJ, et al. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention? J Hypertens 1996; 14:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/6\">",
"      Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011; 124:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/7\">",
"      Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001; 14:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/8\">",
"      de Vries RJ, van Veldhuisen DJ, Dunselman PH. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. Am Heart J 2000; 139:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/9\">",
"      Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/10\">",
"      Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/11\">",
"      Leader S, Mallick R, Roht L. Using medication history to measure confounding by indication in assessing calcium channel blockers and other antihypertensive therapy. J Hum Hypertens 2001; 15:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/12\">",
"      Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/13\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/14\">",
"      Lubsen J, Wagener G, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/15\">",
"      Hart P, Bakris GL. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int 2008; 73:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/16\">",
"      Pahor M, Guralnik JM, Corti MC, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/17\">",
"      Pahor M, Guralnik JM, Furberg CD, et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/18\">",
"      Pahor M, Guralnik JM, Salive ME, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/19\">",
"      Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/20\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/21\">",
"      Kizer JR, Kimmel SE. Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. Arch Intern Med 2001; 161:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/22\">",
"      Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/23\">",
"      Eisenberg MJ, Brox A, Bestawros AN. Calcium channel blockers: an update. Am J Med 2004; 116:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32966/abstract/24\">",
"      Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289:2073.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3832 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-BC92F1AF1C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32966=[""].join("\n");
var outline_f32_12_32966=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF CALCIUM CHANNEL BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dihydropyridines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Non-dihydropyridines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      KNOWN SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Effects on cardiac function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Use in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SERIOUS ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Increased mortality after acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Increased risk for acute MI in hypertensive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Short- versus long-acting calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Increased mortality, gastrointestinal bleeding, and cancer in the elderly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3832\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3832|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/14/17645\" title=\"figure 1\">",
"      Short acting nifedipine in CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/33/29213\" title=\"figure 2\">",
"      Calcium blockers and MI risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3832|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/33/15899\" title=\"table 1\">",
"      Short versus long acting CCBs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31736?source=related_link\">",
"      Calcium channel blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30438?source=related_link\">",
"      Calcium channel blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40469?source=related_link\">",
"      Calcium channel blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/57/39831?source=related_link\">",
"      Calcium channel blockers in the treatment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=related_link\">",
"      Choice of therapy in essential hypertension: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28246?source=related_link\">",
"      Management of severe asymptomatic hypertension (hypertensive urgencies)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_12_32967="ECG bundle branch reentrant ventricular tachcardia";
var content_f32_12_32967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Surface 12-lead ECG in bundle branch reentrant ventricular tachcardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: 12 lead ECG during sinus rhythm; there is a left bundle branch block-type intraventricular conduction delay. Right panel: 12 lead ECG during ventricular tachycardia; there is a remarkable similarity in QRS morphology during VT and sinus rhythm. The HV interval during sinus rhythm was 65 msec, suggesting underlying His-Purkinje conduction disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32967=[""].join("\n");
var outline_f32_12_32967=null;
var title_f32_12_32968="Diagnosis of myasthenia gravis";
var content_f32_12_32968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of myasthenia gravis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/12/32968/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/12/32968/contributors\">",
"     Shawn J Bird, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/12/32968/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/12/32968/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/12/32968/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/12/32968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/12/32968/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/12/32968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis is the most common disorder of neuromuscular transmission. It is now one of the best characterized and understood autoimmune disorders. The hallmark of the disorder is a fluctuating degree and variable combination of weakness in ocular, bulbar, limb, and respiratory muscles. Weakness is the result of an antibody-mediated, T-cell dependent immunologic attack directed at proteins in the postsynaptic membrane of the neuromuscular junction (acetylcholine receptors or receptor-associated proteins). The diagnosis of myasthenia gravis can be established by clinical and serologic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the diagnosis of myasthenia gravis. Other aspects of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=see_link\">",
"     \"Pathogenesis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15654?source=see_link\">",
"     \"Differential diagnosis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link\">",
"     \"Treatment of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to myasthenia is focused on confirming the clinical diagnosis established by the history and typical examination findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bedside tests (the Tensilon test and the ice pack test) are easy to perform and are sensitive, but they have major limitations due to concerns about excess false-positive results. Confirmation by these tests alone is unwise.",
"   </p>",
"   <p>",
"    More reliable laboratory methods that aid in the confirmation are serologic tests for autoantibodies and electrophysiologic studies (repetitive nerve stimulation studies and single-fiber EMG). It should be kept in mind that the diagnostic sensitivity of these studies also varies considerably depending on whether the patient has ocular or generalized disease.",
"   </p>",
"   <p>",
"    The approximate diagnostic sensitivity of the confirmatory tests in myasthenia is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef77349 \" href=\"mobipreview.htm?18/3/18491\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BEDSIDE TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ice pack test and the Tensilon (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    ) test should, in large part, be considered an extension of the neurologic examination rather than laboratory tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ice pack test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ice pack test can be used in patients with ptosis, particularly those in whom the Tensilon (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    ) test is considered too risky. It is not helpful for those with extraocular muscle weakness. Since it is based on the physiologic principle of improving neuromuscular transmission at lower muscle temperatures, the eyelid muscles are the most easily cooled by the application of ice.",
"   </p>",
"   <p>",
"    In the ice pack test, a bag (or surgical glove) is filled with ice and placed on the closed lid for two minutes. The ice is then removed and the extent of ptosis is immediately assessed. The sensitivity appears to be about 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] in those with prominent ptosis. The predictive value of the test has not yet been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tensilon test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    (Tensilon) test should be used only in those patients with obvious ptosis or ophthalmoparesis, in whom improvement after infusion of the drug can easily be observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/5\">",
"     5",
"    </a>",
"    ]. The difficulty in quantifying strength independent of volition in other muscle groups makes the interpretation of the response to Tensilon too unreliable.",
"   </p>",
"   <p>",
"    Commercial production of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    , which stopped in February 2008, resumed in 2009 after rights to the product were acquired by Bioniche Pharma, and the shortage of edrophonium is now resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35156?source=see_link\">",
"     Edrophonium",
"    </a>",
"    chloride is an acetylcholinesterase inhibitor with rapid onset (30 to 45 seconds) and short duration of action (5 to 10 minutes). This agent prolongs the presence of acetylcholine in the neuromuscular junction and results in an immediate increase in muscle strength in many of the affected muscles.",
"   </p>",
"   <p>",
"    To perform the test, 1 mL of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    should be drawn up in a 1 cc tuberculin syringe, with an initial 2 mg test dose given intravenously. This can be followed by another 2 mg dose every 60 seconds up to a total dose of 10 mg. This incremental administration has a number of advantages. Most patients respond by the time 4 or 6 mg is delivered. Since the patient may not need the full 10 mg dose to see a positive response, excessive muscarinic side effects can often be avoided by this approach. In addition, in some patients the ocular muscles may strengthen at lower doses but then show a paradoxical response and weaken at higher doses of edrophonium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/7\">",
"     7",
"    </a>",
"    ]. The incremental administration of edrophonium will not miss that window of effectiveness.",
"   </p>",
"   <p>",
"    The injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    also potentiates the muscarinic effects of acetylcholine and is not without risk, especially in the elderly, or those with cardiac disease or bronchial asthma. These medical conditions are relative contraindications for the Tensilon test. Patients frequently develop increased salivation and mild gastrointestinal cramping. More seriously, symptomatic bradycardia or bronchospasm can occur.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    (0.4 to 0.6 mg) should be ready in a separate syringe before the edrophonium is administered. Atropine can then be readily delivered intravenously should these adverse effects occur. Cardiac monitoring or avoiding this test altogether is prudent in the elderly or those with a history of arrhythmia or heart disease.",
"   </p>",
"   <p>",
"    The sensitivity of the Tensilon test is in the range of 80 to 90 percent, but it is associated with many false-negative and false-positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Some patients with clearly established myasthenia gravis may have equivocal or no response to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    . On the other hand, a positive test is not specific for myasthenia, as it can also occur in other conditions, such as motor neuron disease, brainstem tumors, and compressive cranial neuropathies, which can present in a similar fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SEROLOGIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis is a condition that fulfills all the major criteria for a disorder mediated by autoantibodies against the acetylcholine receptor (AChR-Ab) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/1\">",
"     1",
"    </a>",
"    ], or against a receptor-associated protein, muscle specific tyrosine kinase (MuSK-Ab). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=see_link\">",
"     \"Pathogenesis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with positive AChR-Ab or MuSK-Ab assays have seropositive myasthenia gravis (SPMG). Demonstration of these antibodies, possible in 88 to 94 percent of patients with generalized disease, provides the laboratory confirmation of myasthenia gravis. In those with purely ocular myasthenia, the sensitivity of AChR-Ab testing is considerably lower, detectable in about half of patients. There are rare cases of ocular myasthenia that are MuSK-Ab positive, but most large case series of ocular myasthenia gravis have not found patients who are MuSK-Ab positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acetylcholine receptor antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An immunologic assay to detect the presence of circulating acetylcholine receptor antibodies (AChR-Ab) is the first step in the laboratory confirmation of myasthenia. There are three AChR-Ab assays: binding, blocking, and modulating. Most authors use the term AChR-Ab as synonymous with the binding antibodies and these are what are referred to in most studies that report the diagnostic sensitivity of these tests in myasthenia gravis for the reasons discussed below. These antibodies are polyclonal and are present in approximately 80 to 90 percent of patients with generalized disease. Essentially all patients (98 to 100 percent) with myasthenia gravis and thymoma are seropositive for these antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The assay for the binding antibody is the most sensitive. One study found these antibodies in 93, 88, and 71 percent of individuals with moderate to severe generalized myasthenia gravis, mild generalized myasthenia, and ocular myasthenia, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/10\">",
"       10",
"      </a>",
"      ]. Others have found binding AChR-Abs antibodies in 80 to 90 percent of those with generalized disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/7,11,12\">",
"       7,11,12",
"      </a>",
"      ], and in 40 to 55 percent of those with ocular myasthenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Binding AChR antibodies are measured by standard radioimmunoassay and are highly specific for myasthenia gravis. There are virtually no false-positive results in healthy or disease-matched populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. There are rare false positives in low titers in Lambert-Eaton myasthenic syndrome (5 percent), motor neuron disease (3 to 5 percent), and polymyositis (&lt;1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/10,15,16\">",
"       10,15,16",
"      </a>",
"      ]. They are also rarely seen in some disorders that are not usually confused with myasthenia: primary biliary cirrhosis, systemic lupus erythematosus, thymoma without myasthenia, and in first-degree relatives of patients with myasthenia gravis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/2,17,18\">",
"       2,17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blocking AChR-Ab are present in about half of patients with generalized disease. They are present in fewer than 1 percent of patients with negative binding antibodies, but they have no significant false positives.",
"     </li>",
"     <li>",
"      Assays for modulating AChR-Ab increase the sensitivity by &le;5 percent when added to the binding studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/12\">",
"       12",
"      </a>",
"      ], and false-positive results are more of a problem [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Binding antibody studies are sufficient in most circumstances. The demonstration of blocking antibodies may be helpful if a possible false-positive binding antibody result is suspected.",
"   </p>",
"   <p>",
"    AChR-Ab titers correlated poorly with disease severity between patients. A low-titer or even antibody-negative patient may have much more severe clinical disease than a patient with high titers. However, in an individual patient, the titers tend to fall with successful immunotherapy, and they parallel clinical improvement.",
"   </p>",
"   <p>",
"    Ideally, serologic testing for AChR-Ab should be performed prior to initiating immune modulating therapy for myasthenia gravis, as such therapy can sometimes lead to apparent seronegativity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/12\">",
"     12",
"    </a>",
"    ]. In one cohort of 143 seropositive patients, 9 percent became seronegative after treatment when retested in clinical remission. In addition, repeat serologic testing 6 to 12 months after initial testing has been reported to detect positive seroconversion in approximately 15 percent of patients with myasthenia gravis who were initially seronegative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/12,19\">",
"     12,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     MuSK antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to the muscle specific receptor tyrosine kinase (MuSK) are present in 38 to 50 percent of those with generalized myasthenia gravis who are AChR-Ab negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/7,12,20-26\">",
"     7,12,20-26",
"    </a>",
"    ]. MuSK is a receptor tyrosine kinase that mediates agrin-dependent AChR clustering and neuromuscular junction formation during development. MuSK antibody positive myasthenia gravis may have a different cause and pathologic mechanism than AChR-Ab positive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/20,27\">",
"     20,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis of myasthenia gravis\", section on 'MuSK antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MuSK antibodies are generally not present in those with well-established ocular myasthenia gravis, but they have been detected in a few cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Although nearly half of patients with AChR-Ab negative myasthenia gravis will have MuSK antibodies, those with AChR-Ab positive myasthenia do not have antibodies to MuSK in most studies to date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/20-25\">",
"     20-25",
"    </a>",
"    ]. However, one group found that 11 percent of patients with AChR-Ab positive myasthenia did have antibodies to MuSK as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/30\">",
"     30",
"    </a>",
"    ]. MuSK antibodies appear to be much less common in some AChR-Ab negative myasthenia populations, being found in only 1 of 27 Taiwanese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/31\">",
"     31",
"    </a>",
"    ] and 0 of 17 Scandinavian patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One consistent finding is that patients with AChR-Ab negative myasthenia gravis and MuSK antibodies have a much lower frequency of thymic pathology than patients with AChR-Ab positive myasthenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. The group of patients with MuSK antibodies is not associated with the presence of underlying thymoma. In addition, thymic hyperplasia is frequent in AChR-Ab positive myasthenia, but this pathology is much less frequent in the MuSK-Ab positive group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis of myasthenia gravis\", section on 'MuSK antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the appropriate clinical setting (lack of AChR-Ab and typical clinical features listed below), MuSK antibody testing can clarify the diagnosis and perhaps direct treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the initial management of clinically apparent myasthenia should be the same for patients with or without AChR antibodies; this would change only if future studies find additional therapeutic differences related to MuSK antibody status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AChR-Ab negative myasthenia gravis who are MuSK-Ab positive share most of the clinical manifestations of generalized myasthenia. In addition, the following observations have been made regarding the clinical features of AChR-Ab negative, MuSK-Ab positive myasthenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/21,26,37-40\">",
"     21,26,37-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset at any age",
"     </li>",
"     <li>",
"      Female preponderance",
"     </li>",
"     <li>",
"      An oculobulbar form with diplopia, ptosis, and dysarthria; not purely ocular myasthenia gravis",
"     </li>",
"     <li>",
"      A restricted myopathic form with prominent respiratory",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proximal weakness, especially neck extension",
"     </li>",
"     <li>",
"      No thymic pathology (thymoma) and uncertain role of thymectomy",
"     </li>",
"     <li>",
"      Less responsiveness to acetylcholinesterase inhibitors",
"     </li>",
"     <li>",
"      Good responsiveness to plasma exchange and immunosuppression, with the possible exception of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Seronegative myasthenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term seronegative myasthenia gravis, also called antibody-negative myasthenia gravis, refers to the 6 to 12 percent of patients with myasthenia who have negative standard assays for both AChR antibodies and MuSK antibodies. The term was previously used only for those who were AChR antibody negative, regardless of MuSK antibody status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis of myasthenia gravis\", section on 'Double-seronegative myasthenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with seronegative myasthenia gravis are more likely to have purely ocular disease than those who are seropositive. There is also a trend for those with generalized seronegative myasthenia to have a better outcome after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seronegative myasthenia gravis is an autoimmune disorder with most of the same features as seropositive myasthenia gravis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/19,26\">",
"     19,26",
"    </a>",
"    ]. The electrophysiologic findings are identical. Patients with seronegative myasthenia respond in a similar fashion to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    , plasma exchange, glucocorticoids, and immunosuppressive therapies, as well as thymectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-striated muscle antibodies are heterogeneous with specificity against striated muscle proteins. They are present in 30 percent of patients with myasthenia, but in 80 percent of those with thymoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/7\">",
"     7",
"    </a>",
"    ]. These antibodies may be a useful marker for thymoma in those patients between 20 and 50 years of age. In this cohort, thymoma can be found in 60 percent of patients with anti-striated muscle antibodies, but in less than 2 percent of those without these antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/41\">",
"     41",
"    </a>",
"    ]. The false-positive rate (striational antibodies present without thymoma) is about 10 percent, but it rises to 50 percent in those over age 50. Under age 20, the likelihood of thymoma is low.",
"   </p>",
"   <p>",
"    Measurement of other skeletal muscle protein antibodies may potentially be more helpful than striational antibodies in predicting the presence of a thymoma and assessing disease prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. One study demonstrated that antibodies to titin, an intracellular muscle protein, were found in 95 percent of patients with myasthenia gravis and thymoma, but also 50 percent of those without thymoma. The positive predictive value of these antibodies was only 39 percent, but the negative predictive value was 99 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/44\">",
"     44",
"    </a>",
"    ]. Assays for antibodies to the ryanodine receptor had a lower sensitivity (70 percent), but a greater specificity (95 percent) and positive predictive value (70 percent). CT scanning for thymoma, in comparison, had a sensitivity, positive predictive value, and negative predictive value of 73, 49, and 65 percent, respectively.",
"   </p>",
"   <p>",
"    These antibodies to titin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ryanodine are found primarily in late-onset myasthenia gravis. In this population of patients, along with positive AChR antibodies, the presence of these antibodies may raise the clinical suspicion of thymoma. Alternatively, the absence of anti-titin antibodies makes the presence of thymoma unlikely. Some data suggest that the presence of these antibodies predicts more severe disease and an unsatisfactory outcome after thymectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGIC CONFIRMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic studies are an important supplement to the immunologic studies and may also provide confirmation of the diagnosis of myasthenia. Repetitive nerve stimulation (RNS) studies and single-fiber electromyography (SFEMG) have a diagnostic sensitivity in generalized myasthenia of about 75 percent and 95 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/7,46\">",
"     7,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13962?source=see_link\">",
"     \"Electrodiagnostic evaluation of the neuromuscular junction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Repetitive nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive nerve stimulation (RNS) studies for myasthenia gravis are reviewed here and discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13962?source=see_link&amp;anchor=H9468271#H9468271\">",
"     \"Electrodiagnostic evaluation of the neuromuscular junction\", section on 'Repetitive nerve stimulation (RNS)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to their wide availability, RNS studies are the most frequently used electrodiagnostic test for myasthenia gravis. The test is performed by placing the recording electrode over the endplate region of a muscle and stimulating the motor nerve to that muscle. The nerve is electrically stimulated 6 to 10 times at low rates (2 or 3 Hertz). The compound muscle action potential (CMAP) amplitude is recorded from the electrodes over the muscle after electrical stimulation of the nerve. In normal muscles, there is no change in CMAP amplitude with repetitive nerve stimulation. In myasthenia there may be a progressive decline in the CMAP amplitude with the first four to five stimuli (a decremental response).",
"   </p>",
"   <p>",
"    An RNS study is considered positive if the decrement is greater than 10 percent (",
"    <a class=\"graphic graphic_waveform graphicRef75502 \" href=\"mobipreview.htm?12/36/12879\">",
"     waveform 1",
"    </a>",
"    ). It is important to sample distal and proximal muscle to maximize the yield. Distal muscles are technically easier, but they have a lower diagnostic sensitivity. If possible, clinically weak muscles should be included as well. To maximize the sensitivity, the muscles tested should be warm, and acetylcholinesterase inhibitors should be held for 12 hours before the study.",
"   </p>",
"   <p>",
"    A suitable RNS study usually consists of low-rate (at 2 or 3 Hz) stimulation with one or two trains of 6 to 10 stimuli and CMAP recordings at rest, followed by an exercise protocol. In the exercise protocol, the patient is asked to exercise the muscle maximally for 30 to 60 seconds. A train of stimuli is performed immediately after exercise. A repair of the CMAP decremental response (a smaller percent decrement compared with the decrement seen at rest) is commonly seen, reflecting post-exercise or post-activation facilitation. An additional train of stimuli is delivered at one, three, and five minutes after exercise. This may result in a larger decrement than seen at rest, termed post-exercise or post-activation exhaustion. This exercise protocol may increase the sensitivity of RNS by an additional 5 to 10 percent.",
"   </p>",
"   <p>",
"    RNS studies are positive in about 75 percent of patients with generalized myasthenia if recordings are made from proximal (usually trapezius and orbicularis oculi), as well as distal muscles. RNS studies are positive in approximately 50 percent of patients with ocular myasthenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/7,46\">",
"     7,46",
"    </a>",
"    ]. A decremental response is not specific for myasthenia gravis. Decrements may be seen in other disorders of neuromuscular transmission (LEMS or botulism) and motor neuron disease. These disorders should not cause electrodiagnostic confusion when combined with studies looking for presynaptic disorders of neuromuscular transmission and standard needle electromyography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Single-fiber electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single-fiber electromyography (SFEMG) is reviewed here briefly and discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13962?source=see_link&amp;anchor=H9468341#H9468341\">",
"     \"Electrodiagnostic evaluation of the neuromuscular junction\", section on 'Single fiber electromyography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SFEMG is more technically demanding than RNS and is less widely available, but it is the most sensitive diagnostic test for myasthenia gravis. A specialized needle electrode with a 25 &micro;m recording window and the low frequency filters set at 500 Hz allow simultaneous recording of the action potentials of two muscle fibers innervated by the same motor axon. The variability in time of the second action potential relative to the first is called \"jitter.\" Any disorder, such as myasthenia gravis, that reduces the safety factor of transmission at the neuromuscular junction will produce increased jitter. To maximize the sensitivity, a limb and facial muscle may be studied.",
"   </p>",
"   <p>",
"    SFEMG is positive in greater than 95 percent of those with generalized myasthenia. In ocular myasthenia gravis, it ranges from 85 to 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/7,46\">",
"     7,46",
"    </a>",
"    ]. Abnormal jitter is not specific for myasthenia. It may be abnormal in motor neuron disease, polymyositis, peripheral neuropathy, LEMS, and other neuromuscular disorders. However, it is specific for a disorder of neuromuscular transmission when no other abnormalities are seen on standard needle EMG examination. The exception may be in differentiating patients suspected of ocular myasthenia gravis from those with Kearns-Sayre syndrome (KSS) causing chronic progressive external ophthalmoplegia (CPEO). Two reports give conflicting data: in the presence of a normal needle EMG examination, one showed abnormal SFEMG in CPEO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/47\">",
"     47",
"    </a>",
"    ], and the other did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ASSOCIATED CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymic tumors and certain autoimmune disorders are seen in association with myasthenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Thymic tumors and other malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thymus is intimately involved in the pathogenesis of myasthenia gravis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=see_link\">",
"     \"Pathogenesis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is postulated that all patients with myasthenia have B cells that produce AChR-Ab in the thymus. In addition, 75 percent of patients with myasthenia have thymic abnormalities. Thymic hyperplasia is most common (85 percent), but various tumors (primarily thymoma) are present in up to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/49\">",
"     49",
"    </a>",
"    ]. The thymic tumors are usually noninvasive cortical thymomas, but invasive thymic carcinoma can occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/43/4794?source=see_link\">",
"     \"Pathology of mediastinal tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8474?source=see_link\">",
"     \"Clinical presentation and management of thymoma and thymic carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging of the mediastinum (by either computed tomography or MRI) is an important component of the evaluation of any patient with myasthenia gravis. The detection, or absence, of striational antibodies and antibodies directed against titin and the ryanodine receptor may be helpful in predicting the presence (or absence) of thymoma (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Other antibodies'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Myasthenia gravis can be considered a paraneoplastic effect of thymoma, but not of extrathymic tumors. Nonetheless, myasthenia has been associated with extrathymic tumors, such as small cell lung cancer and Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32968/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. It is uncertain from these studies whether this co-occurrence represents a true association. The data do not warrant an extensive search for malignancy, other than thymoma, in myasthenics, even in older patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune thyroid disease is quite common (3 to 8 percent) in patients with myasthenia. Thus, screening for thyroid abnormalities should also be part of the initial evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30057?source=see_link\">",
"     \"Neurologic manifestations of hyperthyroidism and Graves' disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36585?source=see_link\">",
"     \"Neurologic manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although less common than thyroid disease, rheumatoid arthritis and systemic lupus erythematosus are more often associated with myasthenia than in age-matched patients without myasthenia. The clinician should be alert to the possibility of coexistent rheumatoid arthritis and SLE and perform the appropriate serologic studies and evaluation, if there are suggestive historical or examination features of these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of myasthenia gravis includes conditions that mimic ocular myasthenia (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/53/7001?source=see_link&amp;anchor=H8#H8\">",
"     \"Ocular myasthenia gravis\", section on 'Differential diagnosis'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thyroid ophthalmopathy",
"     </li>",
"     <li>",
"      Kearns-Sayre syndrome",
"     </li>",
"     <li>",
"      Brainstem and motor cranial nerve pathology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential also includes conditions that mimic generalized myasthenia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Generalized fatigue (\"tiredness\")",
"     </li>",
"     <li>",
"      Motor neuron disease (ALS)",
"     </li>",
"     <li>",
"      Lambert-Eaton myasthenic syndrome (LEMS)",
"     </li>",
"     <li>",
"      Botulism",
"     </li>",
"     <li>",
"      Penicillamine-induced myasthenia",
"     </li>",
"     <li>",
"      Congenital myasthenic syndromes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further studies to exclude other diseases in the differential diagnosis of myasthenia gravis are indicated in selected patients. For those with ocular or bulbar symptoms, an MRI of the brain is appropriate. CT scanning or ultrasonography of the orbits is helpful in the differential diagnosis of ocular myasthenia and thyroid ophthalmopathy. In cases of possible multiple cranial nerve abnormalities, examination of the cerebrospinal fluid for abnormal cells and cytology is usually necessary.",
"   </p>",
"   <p>",
"    The differential diagnosis of myasthenia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15654?source=see_link\">",
"     \"Differential diagnosis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/14/14562?source=see_link\">",
"       \"Patient information: Myasthenia gravis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to the diagnosis of myasthenia gravis varies with the clinical setting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first step is to establish that the symptoms and signs are consistent with myasthenia gravis and not another disorder. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnostic approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Keeping in mind its limitations, the bedside ice pack test can be used to support the diagnosis of myasthenia gravis in patients with ptosis, but it is NOT helpful for those with extraocular muscle weakness. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ice pack test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35156?source=see_link\">",
"       edrophonium",
"      </a>",
"      (Tensilon) test should be used only in those patients with obvious ptosis or ophthalmoparesis, in whom improvement after infusion of the drug can easily be observed. The sensitivity of the Tensilon test for the diagnosis of MG is in the range of 80 to 90 percent, but it is associated with many false-negative and false-positive results. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Tensilon test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all patients with the clinical diagnosis of myasthenia, the diagnosis should be confirmed, if possible, by immunologic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      electrophysiologic testing (",
"      <a class=\"graphic graphic_table graphicRef77349 \" href=\"mobipreview.htm?18/3/18491\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Because of its specificity, testing for autoantibodies against the acetylcholine receptor (AChR-Ab) should be performed on all patients. Demonstration of binding antibodies, possible in 80 to 90 percent of patients with generalized disease, provides the laboratory confirmation of myasthenia gravis. In select patients, assays for blocking and modulating antibodies may also be helpful. If the AChR-Abs are negative, an assay for antibodies to muscle specific tyrosine kinase (MuSK) should be performed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Serologic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibodies to muscle specific tyrosine kinase (MuSK) are present in 38 to 50 percent of those with AChR-Ab negative, generalized myasthenia. Thymic pathology is usually minimal in patients with AChR-Ab negative, MuSK-Ab positive myasthenia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'MuSK antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Seronegative myasthenia gravis, also called antibody-negative myasthenia gravis, refers to the 6 to 12 percent of patients with generalized myasthenia who have a negative standard assay for AChR-Ab and MuSK-Ab. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Seronegative myasthenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repetitive nerve stimulation (RNS) studies and single-fiber electromyography (SFEMG) have a diagnostic sensitivity in generalized myasthenia of about 75 percent and 95 percent, respectively. RNS studies should be performed first, followed by SFEMG, if the diagnosis is still uncertain. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Electrophysiologic confirmation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrophysiologic tests usually allow confirmation of the diagnosis in patients who have seronegative myasthenia gravis. They may be helpful in those with positive antibody studies as well, particularly if there are any unusual clinical features or a lack of response to immunotherapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Electrophysiologic confirmation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies to exclude other diseases in the differential diagnosis of myasthenia gravis are also indicated in selected patients. For those with ocular or bulbar symptoms, an MRI of the brain is appropriate. CT scanning or ultrasound of the orbits is helpful in the differential diagnosis of ocular myasthenia and thyroid ophthalmopathy. Lumbar puncture may be necessary to exclude lymphomatous or carcinomatous meningitis with certain clinical presentations. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood tests should include thyroid function tests. If there is clinical suspicion of an associated rheumatologic disorder, assays for antinuclear antibody and rheumatoid factor should also be performed. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Autoimmune disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of myasthenia gravis has been established, a chest CT or MRI scan should be performed to look for a possible associated thymoma. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Thymic tumors and other malignancies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tests for striational antibodies may help with weighing the likelihood of thymoma. When assays for titin and the ryanodine receptor are more widely available commercially, they will also likely help in this regard. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Other antibodies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/1\">",
"      Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/2\">",
"      Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004; 29:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/3\">",
"      Sethi KD, Rivner MH, Swift TR. Ice pack test for myasthenia gravis. Neurology 1987; 37:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/4\">",
"      Golnik KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of myasthenia gravis. Ophthalmology 1999; 106:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/5\">",
"      Daroff RB. The office Tensilon test for ocular myasthenia gravis. Arch Neurol 1986; 43:843.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Resolved Drug Shortages. www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050793.htm (Accessed June 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/7\">",
"      Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol 2004; 24:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/8\">",
"      Phillips LH 2nd, Melnick PA. Diagnosis of myasthenia gravis in the 1990s. Semin Neurol 1990; 10:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/9\">",
"      Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004; 10:7270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/10\">",
"      Lennon, VA. Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology 1997; 48:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/11\">",
"      Vincent A, McConville J, Farrugia ME, et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 2003; 998:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/12\">",
"      Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 2007; 36:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/13\">",
"      Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/14\">",
"      Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/15\">",
"      Howard FM Jr, Lennon VA, Finley J, et al. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987; 505:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/16\">",
"      Mittag TW, Caroscio J. False-positive immunoassay for acetylcholine-receptor antibody in amyotrophic lateral sclerosis. N Engl J Med 1980; 302:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/17\">",
"      Sundewall AC, Lefvert AK, Olsson R. Anti-acetylcholine receptor antibodies in primary biliary cirrhosis. Acta Med Scand 1985; 217:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/18\">",
"      Pascuzzi RM, Phillips LH 2nd, Johns TR, Lennon VA. The prevalence of electrophysiological and immunological abnormalities in asymptomatic relatives of patients with myasthenia gravis. Ann N Y Acad Sci 1987; 505:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/19\">",
"      Sanders DB, Andrews PI, Howard Jr JF, Massey JM. Seronegative myasthenia gravis. Neurology 1997; 48:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/20\">",
"      McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/21\">",
"      Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003; 60:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/22\">",
"      Vincent A, McConville J, Farrugia ME, Newsom-Davis J. Seronegative myasthenia gravis. Semin Neurol 2004; 24:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/23\">",
"      Nemoto Y, Kuwabara S, Misawa S, et al. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry 2005; 76:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/24\">",
"      Lavrnic D, Losen M, Vujic A, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005; 76:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/25\">",
"      Zhou L, McConville J, Chaudhry V, et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 2004; 30:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/26\">",
"      Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 2007; 68:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/27\">",
"      Lindstrom J. Is \"seronegative\" MG explained by autoantibodies to MuSK? Neurology 2004; 62:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/28\">",
"      Caress JB, Hunt CH, Batish SD. Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 2005; 62:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/29\">",
"      Hanisch F, Eger K, Zierz S. MuSK-antibody positive pure ocular myasthenia gravis. J Neurol 2006; 253:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/30\">",
"      Ohta K, Shigemoto K, Kubo S, et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 2004; 62:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/31\">",
"      Yeh JH, Chen WH, Chiu HC, Vincent A. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology 2004; 62:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/32\">",
"      Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 2005; 12:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/33\">",
"      Willcox N, Schluep M, Ritter MA, Newsom-Davis J. The thymus in seronegative myasthenia gravis patients. J Neurol 1991; 238:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/34\">",
"      Verma PK, Oger JJ. Seronegative generalized myasthenia gravis: low frequency of thymic pathology. Neurology 1992; 42:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/35\">",
"      Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005; 64:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/36\">",
"      Leite MI, Str&ouml;bel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005; 57:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/37\">",
"      Scuderi F, Marino M, Colonna L, et al. Anti-p110 autoantibodies identify a subtype of \"seronegative\" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002; 82:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/38\">",
"      Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/39\">",
"      Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003; 2:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/40\">",
"      Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010; 41:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/41\">",
"      Sanders, DB, Massey, JM. The diagnostic utility of anti-striational antibodies in myasthenia gravis. Neurology 2002; 58:A229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/42\">",
"      Voltz RD, Albrich WC, N&auml;gele A, et al. Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology 1997; 49:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/43\">",
"      Gautel M, Lakey A, Barlow DP, et al. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 1993; 43:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/44\">",
"      Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005; 62:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/45\">",
"      Chen XJ, Qiao J, Xiao BG, Lu CZ. The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis. J Neurol 2004; 251:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/46\">",
"      Oh SJ, Kim DE, Kuruoglu R, et al. Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 1992; 15:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/47\">",
"      Krendel DA, Sanders DB, Massey JM. Single fiber electromyography in chronic progressive external ophthalmoplegia. Muscle Nerve 1987; 10:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/48\">",
"      Milone M, Monaco ML, Evoli A, et al. Ocular myasthenia: diagnostic value of single fibre EMG in the orbicularis oculi muscle. J Neurol Neurosurg Psychiatry 1993; 56:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/49\">",
"      Castleman B. The pathology of the thymus gland in myasthenia gravis. Ann N Y Acad Sci 1966; 135:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/50\">",
"      Fujita J, Yamadori I, Yamaji Y, et al. Myasthenia gravis associated with small-cell carcinoma of the lung. Chest 1994; 105:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/51\">",
"      Levin N, Abramsky O, Lossos A, et al. Extrathymic malignancies in patients with myasthenia gravis. J Neurol Sci 2005; 237:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32968/abstract/52\">",
"      Abrey LE. Association of myasthenia gravis with extrathymic Hodgkin's lymphoma: complete resolution of myasthenic symptoms following antineoplastic therapy. Neurology 1995; 45:1019.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5130 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-9E6818F356-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32968=[""].join("\n");
var outline_f32_12_32968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BEDSIDE TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ice pack test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tensilon test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SEROLOGIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acetylcholine receptor antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MuSK antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Seronegative myasthenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ELECTROPHYSIOLOGIC CONFIRMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Repetitive nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Single-fiber electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ASSOCIATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Thymic tumors and other malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5130\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5130|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/3/18491\" title=\"table 1\">",
"      Sensitivity of tests for MG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5130|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?12/36/12879\" title=\"waveform 1\">",
"      RNS study MG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8474?source=related_link\">",
"      Clinical presentation and management of thymoma and thymic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15654?source=related_link\">",
"      Differential diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13962?source=related_link\">",
"      Electrodiagnostic evaluation of the neuromuscular junction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30057?source=related_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36585?source=related_link\">",
"      Neurologic manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/53/7001?source=related_link\">",
"      Ocular myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=related_link\">",
"      Pathogenesis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/43/4794?source=related_link\">",
"      Pathology of mediastinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/14/14562?source=related_link\">",
"      Patient information: Myasthenia gravis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=related_link\">",
"      Treatment of myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_12_32969="Cushings disease MRI I";
var content_f32_12_32969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75003%7EENDO%2F50905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75003%7EENDO%2F50905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging in Cushing's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thirty-seven-year-old woman with Cushing's disease caused by a 9 x 11 x 14 mm corticotroph macroadenoma. Left panel: Coronal section of unenhanced MR image of the sella turcica. The macroadenoma appears as an area of decreased signal intensity impinging upon the optic chasm above and the sphenoid sinus below (arrows). Right panel: Coronal gadolinium-enhanced MR image of the sella turcica. The microadenoma appears as an area of enhanced signal intensity with some areas of nonhomogeneity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Williams Textbook of Endocrinology, 8th ed, Foster, DW, Wilson, JD (Eds), WB Saunders, Philadelphia, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging in Cushing's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MR images (coronal sections) of the sella turcica in the same patient with Cushing's disease. Left: Unenhanced image shows that most of the right side of the pituitary gland is occupied by an area of decreased signal intensity (arrows). Right: Gadolinium-enhanced image more clearly shows a 6 mm microadenoma as an area of decreased signal intensity (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Williams Textbook of Endocrinology, 8th ed, Foster, DW, Wilson, JD (Eds), WB Saunders, Philadelphia, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32969=[""].join("\n");
var outline_f32_12_32969=null;
var title_f32_12_32970="Cocaine abuse and dependence in adults";
var content_f32_12_32970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cocaine abuse and dependence in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/12/32970/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/12/32970/contributors\">",
"     David A Gorelick, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/12/32970/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/12/32970/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/12/32970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/12/32970/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/12/32970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine is a tropane ester alkaloid found in leaves of the Erythroxylum coca plant, a bush that grows in the Andes Mountain region of South America. Its stimulant properties have been known to the indigenous population for at least 2000 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/1\">",
"     1",
"    </a>",
"    ]. Oral use of the coca leaf continues to this day and is not associated with significant abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little attention was paid to coca outside South America until its active ingredient, cocaine, was isolated from the leaf in 1860 by a German graduate student, Albert Niemann. This spawned the widespread popularity of cocaine-containing consumer products, including patent medicines, wine, and other beverages. One of the most popular was a non-alcoholic drink containing about 0.75 mg of cocaine per ounce: Coca-Cola&reg;. Increasing reports of adverse effects, such as stroke and cardiac arrest, led to strict government controls. Cocaine was removed from Coca-Cola in 1903. It received little medical attention for the next 70 years, until the \"crack\" cocaine epidemic of the 1980s.",
"   </p>",
"   <p>",
"    The 1914 Harrison Narcotic Act limited cocaine to prescription drug status in the United States (US). Cocaine hydrochloride is still legally available in the US as a 4 or 10 percent solution for use as a local or topical anesthetic, although it has largely been replaced in clinical practice by synthetic local anesthetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/3\">",
"     3",
"    </a>",
"    ]. Cocaine is classified as a Schedule II medication under the Controlled Substances Act.",
"   </p>",
"   <p>",
"    This topic addresses the pharmacology and effects of cocaine use and treatment for addiction in adults. Cocaine use by minors is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    .) Specific cardiovascular and pulmonary complications related to cocaine are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34649?source=see_link\">",
"     \"Pulmonary complications of cocaine abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine is used by more than 14 million people worldwide, about 0.3 percent of the global population age 15 to 64 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/4\">",
"     4",
"    </a>",
"    ]. Use and abuse are most prevalent in North America (6.4 million people, 2.2 percent of population older than 14 years) and Central and South America (2.2 million people, 0.8 percent) and in Western and Central Europe (3.9 million people, 1.2 percent). Current use in the United Kingdom and Spain has reached the levels of the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/5\">",
"     5",
"    </a>",
"    ]. Common street names used in the US for cocaine are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef81985 \" href=\"mobipreview.htm?13/58/14252\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is relatively little cocaine use in Africa, Asia, Eastern Europe, and Oceania. This pattern may be due to supply rather than demand factors, because of the difficulty in obtaining cocaine from its only source in South America and the ready availability of alternative synthetic stimulants such as amphetamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cocaine use is by urban men age 15 to 35 years. About 6 percent of current users in the US are adolescents 12 to 17 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/7\">",
"     7",
"    </a>",
"    ]. Cocaine use has declined somewhat among this age group in the last few years, but has remained steady in older groups.",
"   </p>",
"   <p>",
"    About one-quarter of past year cocaine users (more than 1.6 million) meet psychiatric diagnostic criteria for cocaine abuse or dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/7\">",
"     7",
"    </a>",
"    ]. Yet in 2006, less than one million cocaine users received specialty treatment for their cocaine use.",
"   </p>",
"   <p>",
"    Cocaine is the illegal drug most often associated with visits to US hospital emergency departments. In 2005, it was involved in an estimated 31 percent of drug-related emergency department visits (about 450,000 visits), versus about 17 percent (240,000 visits) for marijuana and about 11 percent (165,000 visits) for heroin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/8\">",
"     8",
"    </a>",
"    ]. Almost one-fifth of cocaine-related visits were by patients seeking detoxification; 3.2 percent were for suicide attempts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patterns of use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine is used in a variety of patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The typical \"binge\" involves short periods of heavy use (eg, payday or weekends) separated by longer periods of little or no use. Others may use for an extended period until their finances are exhausted or access to cocaine is interrupted. A small number of users who are self-medicating an underlying neuropsychiatric disorder, such as attention deficit hyperactivity disorder (ADHD) or narcolepsy, may use low doses daily without dose escalation over time.",
"   </p>",
"   <p>",
"    Most cocaine users living in the community do not use very frequently. About half of past year users used less than 12 times in the year; only 2.5 percent used at least 300 times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors for use and abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;While cocaine use occurs in all sociodemographic groups, it is not equally distributed among the US population. The highest prevalence of use is among unemployed men in their 20s with no more than a high school education who live in urban areas.",
"   </p>",
"   <p>",
"    Cocaine use is highly associated with use of other legal and illegal substances and with psychiatric disorders. Cigarette smokers and heavy alcohol drinkers are 10 times more likely than others to be cocaine users. Among current (past month) cocaine users, 92 percent use alcohol and 79 percent smoke cigarettes (73 percent use both) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/7\">",
"     7",
"    </a>",
"    ]. Almost half are heavy drinkers (five or more drinks on the same occasion on at least five days in the past 30 days). Concurrent use of cocaine and alcohol produces a new compound, cocaethylene, which is pharmacologically active (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Metabolism'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Many cocaine users use other substances either to enhance the \"high\" (eg, simultaneous use of opiates [\"speedballing\"]) or to ameliorate adverse effects of intoxication or withdrawal (eg, use of alcohol, cannabis, or benzodiazepines). Current cocaine users are twice as likely as non-users to have symptoms of depressive or anxiety disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/11\">",
"     11",
"    </a>",
"    ]. Among past year cocaine users, almost one-quarter reported serious psychological distress during that year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine users are at high risk for abuse or dependence. Community-based interview surveys suggest that up to one in six persons who use cocaine will become dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/12\">",
"     12",
"    </a>",
"    ]. Heavier users and users who take the drug intravenously or by smoking are more likely to become dependent than lighter users or intranasal and oral users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The greater abuse potential of intravenous or smoked cocaine is attributed to the faster rate of drug delivery to the brain (within 10 seconds), and faster onset of psychological effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This faster onset is associated with a more intense pleasurable response (the so-called \"rate hypothesis\" of psychoactive drug action) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The environment (including family, religious, and social factors) has the strongest influence on initial cocaine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/19\">",
"     19",
"    </a>",
"    ]. Studies of drug use by pairs of fraternal (dizygotic) and identical (monozygotic) twins suggest a significant genetic influence on the risk of developing cocaine abuse or dependence after use has begun. Several promising candidate genes have been identified, including those for dopamine receptors and the dopamine transporter, but no specific gene has been clearly linked with cocaine addiction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine enhances monoamine neurotransmitter (dopamine, norepinephrine, and serotonin) activity in the central and peripheral nervous systems by blocking the presynaptic reuptake pumps (transporters) for these neurotransmitters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Cocaine's positive psychological effects and abuse liability are considered to be due to its enhancement of brain dopamine activity, especially in the so-called corticomesolimbic dopamine reward circuit. Thus, cocaine addiction has been termed a disease of the brain's dopamine reward system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine is unique among stimulant drugs in having a second action of blocking voltage-gated membrane sodium ion channels. This action accounts for its local anesthetic effect, and may contribute to cardiac arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illegal cocaine comes in two forms: base (alkaloid, as in coca leaves) and salt&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Both forms consist of the same cocaine molecule and exert the same pharmacological actions once they reach the brain or other target organ. They differ in physical properties, which allow different routes of administration.",
"   </p>",
"   <p>",
"    Cocaine base (\"crack,\" \"freebase\") can be smoked because it has a relatively low melting point (98&ordm;C) and vaporizes before substantial pyrolytic destruction has occurred. Conversely, it is difficult to dissolve for injection because it is relatively insoluble in water.",
"   </p>",
"   <p>",
"    In contrast, cocaine salt cannot be efficiently smoked because it melts at 195&ordm;C, with substantial breakdown of the cocaine molecule before vaporization. Cocaine salt is readily injected or insufflated (\"snorted\") through the nose; it is highly water soluble, making it easy to dissolve for injection purposes and facilitating absorption across mucus membranes.",
"   </p>",
"   <p>",
"    The average purity of seized cocaine samples is 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/26\">",
"     26",
"    </a>",
"    ]. Added diluents include both inert fillers that resemble cocaine in appearance (such as dextrose, lactose,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , or starch) and active chemicals that either mimic the local anesthetic effect of cocaine (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , or procaine) or provide some psychoactive effect (such as ephedrine, amphetamine, caffeine, or PCP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Street cocaine also may contain contaminants from the preparation process (such as benzene, acetone, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/28\">",
"     28",
"    </a>",
"    ]. The role of diluents and contaminants in the toxicity of illegal cocaine use is not well understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine is readily absorbed through the mucous membranes of the nose and mouth, and from the genitourinary, gastrointestinal, and respiratory tracts. Passive absorption may occur through intact skin or by inhalation of second-hand cocaine smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Such passive exposure can cause adverse effects in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine is rapidly taken up into most body organs, including the heart, kidney, adrenal glands, and liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/34\">",
"     34",
"    </a>",
"    ]. Cocaine (and its hydrolytic metabolites) appears in blood, urine, hair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/35\">",
"     35",
"    </a>",
"    ], sweat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/36\">",
"     36",
"    </a>",
"    ], saliva [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/37\">",
"     37",
"    </a>",
"    ], and breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. It crosses the placenta to appear in meconium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/40\">",
"     40",
"    </a>",
"    ]. Analysis of these tissues and fluids is used for drug detection in workplace, legal, and treatment settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Onset of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of action for cocaine depends on the route of administration. Intravenous and inhaled (smoked) administration results in onset of action within seconds. Intranasal and gastrointestinal administration result in slower onsets of 20 to 30 minutes and up to 90 minutes, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Duration of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of intravenous or inhaled cocaine administration typically last 15 to 30 minutes; effects of intranasal and gastrointestinal administration are about one and three hours, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine is 95 percent metabolized by hydrolysis of its ester bonds to benzoylecgonine (by carboxyesterases in the liver) and to ecgonine methylester (by butyrylcholinesterase in the liver, plasma, brain, lung, and other tissues) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. The remaining 5 percent is N-demethylated to norcocaine by the liver cytochrome P450 microsomal enzyme system. The hydrolytic metabolites appear to be largely inactive. Norcocaine has some pharmacological actions similar to those of cocaine, and is hepatotoxic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoked cocaine produces an additional series of pyrolysis products, the chief of which are anhydroecgonine methylester and noranhydroecgonine methylester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/43,46\">",
"     43,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine use together with alcohol leads to formation of a new compound, cocaethylene, by transesterification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/43\">",
"     43",
"    </a>",
"    ]. Cocaethylene has pharmacological actions similar to, but less potent than, those of cocaine, and has a longer half-life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Formation of cocaethylene may contribute to more severe or longer lasting toxic effects of cocaine when it is used along with alcohol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine is largely eliminated in the urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/43\">",
"     43",
"    </a>",
"    ]. Benzoylecgonine is the metabolite found in highest concentration in urine. It is this metabolite, rather than the parent drug cocaine, that is measured in urine drug tests for cocaine (see",
"    <a class=\"local\" href=\"#H29\">",
"     'Screening'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL EFFECTS OF COCAINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical cocaine doses are 12 to 15 g orally (coca leaf), 20 to 100 mg intranasally, 10 to 50 mg intravenously, and 50 to 200 mg smoked. The intended effects include increased energy, alertness, and sociability; elation or euphoria; and decreased fatigue, need for sleep, and appetite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. The intense pleasurable feeling has been described as a \"total body orgasm\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is wide variability in the acute response to cocaine and poor correlation between cocaine plasma concentrations and toxic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/49,52\">",
"     49,52",
"    </a>",
"    ]. Fatal cases of cocaine intoxication may present with 100-fold differences in plasma cocaine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unintended adverse effects occur with increasing dose, duration of use, or a more efficient route of administration (eg, intravenous or smoked versus intranasal). These effects include dysphoric mood (anxiety, irritability), panic attacks, suspiciousness, paranoia, grandiosity, impaired judgment, and psychotic symptoms such as delusions and hallucinations. Up to 40 percent of non-treatment-seeking cocaine users may experience sleep disturbance, weight loss (due to appetite suppression), paranoia, or hallucinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Concurrent behavioral effects include restlessness, agitation, tremor, dyskinesia, and repetitive or stereotyped behaviors such as picking at the skin or foraging for drugs (\"punding,\" \"hung-up activity\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/55\">",
"     55",
"    </a>",
"    ]. Associated physiological effects include tachycardia, pupil dilation, diaphoresis, and nausea, reflecting stimulation of the sympathetic nervous system.",
"   </p>",
"   <p>",
"    A detailed discussion of the presentation and treatment of cocaine intoxication is presented separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chronic use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic cocaine use can result in either of two distinct pharmacological adaptations: sensitization (increased drug response) and tolerance (decreased drug response) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In animal studies, sensitization results from low-dose, intermittent exposure, while tolerance results from frequent, high-dose, or long-term exposure.",
"   </p>",
"   <p>",
"    The factors that determine sensitization and tolerance in humans, however, are not well understood. Sensitization to the cardiovascular effects of oral cocaine, but not to its psychological effects, has been demonstrated in laboratory studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/58\">",
"     58",
"    </a>",
"    ]. Tolerance to the psychological, cardiovascular, and neuroendocrine effects of cocaine develops after several doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Tolerance to cardiovascular effects may develop more quickly and completely than does tolerance to psychological effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. This rapid tolerance presumably allows binge users to take large cumulative doses of cocaine.",
"   </p>",
"   <p>",
"    Chronic cocaine abuse is associated with cognitive impairment affecting visuo-motor performance, attention, verbal memory, and risk-reward decision-making [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/62\">",
"     62",
"    </a>",
"    ]. These impairments persist for at least several weeks of abstinence.",
"   </p>",
"   <p>",
"    Cocaine use is associated with suicidal ideation and suicide attempts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. The extent to which suicide is a direct consequence of use, rather than an associated sociodemographic or psychological factor, remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Factors associated with increased risk of suicidality among cocaine users include depression, severe cocaine withdrawal, comorbid alcohol or opioid dependence, history of childhood trauma, and family history of suicidality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic cocaine use by any route of administration is associated with increased risk of infection, especially viral hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/69\">",
"     69",
"    </a>",
"    ] and HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic cocaine use does not appear to increase the risk of general anesthesia, as long as the patient has normal cardiovascular parameters at the time of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Withdrawal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cessation of heavy chronic cocaine use results in a withdrawal syndrome that has prominent psychological features but is rarely medically serious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Symptoms include depression, anxiety, fatigue, difficulty concentrating, decreased ability to experience pleasure (anhedonia), increased cocaine craving, increased appetite, increased sleep, and increased dreaming (due to increased REM sleep). An initial period of intense symptoms (commonly termed the \"crash\") may occur, including psychomotor retardation and severe depression with suicidal ideation. However, most users experience milder symptoms that resolve within one to two weeks without treatment.",
"   </p>",
"   <p>",
"    Physical signs of cocaine withdrawal are usually minor and rarely require treatment. These include nonspecific musculoskeletal pain, tremors, chills, and involuntary motor movement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/75\">",
"     75",
"    </a>",
"    ]. The first week of stimulant withdrawal has been associated with myocardial ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/76\">",
"     76",
"    </a>",
"    ], possibly due to coronary vasospasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EFFECTS ON SPECIFIC ORGAN SYSTEMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine euphoria is associated with transient increases in EEG activity followed by longer-lasting increases in activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/77\">",
"     77",
"    </a>",
"    ]. Seizures may occur in persons without a seizure history, even with first time use of cocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. These are usually single, generalized tonic-clonic seizures occurring within 90 minutes of cocaine use.",
"   </p>",
"   <p>",
"    Craving for cocaine is associated with increased activity in the so-called mesocorticolimbic reward circuit in the brain. This includes the inferior frontal-orbitofrontal gyrus, amygdala (thought to mediate stimulus-reward association), anterior cingulate (mediating anticipation of reward), and nucleus",
"    <span class=\"nowrap\">",
"     accumbens/subcallosal",
"    </span>",
"    gyrus (mediating incentive motivation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebral vasoconstriction, cerebrovascular disease, and hemorrhagic and ischemic stroke are increased in cocaine users, even in patients with no other risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/78-80,83,84\">",
"     78-80,83,84",
"    </a>",
"    ]. Etiologic mechanisms include tachycardia and increased blood pressure from sympathetic activation, vasoconstriction, vasospasm, and intravascular thrombosis due to increased platelet aggregation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI, SPECT, and PET imaging in chronic cocaine users demonstrate structural and functional brain abnormalities: cerebral gray matter atrophy and decreased glucose metabolism in the frontal and temporal lobes, small cerebral perfusion defects, increased creatine concentration in parietal white matter (suggesting abnormal energy metabolism), and decreased D2 dopamine receptors in the striatum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/82,85,86\">",
"     82,85,86",
"    </a>",
"    ]. Impairment of behavioral inhibition in cocaine users has been associated with reduced activity in the anterior cingulate and prefrontal cortices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A pathologic study using melanin immunoreactivity found cocaine users to have 16 percent fewer midbrain dopamine neurons than non-using subjects. This and related findings above suggest that cocaine may have a neurotoxic effect on dopamine neurons, contributing to cocaine dependence in some users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/87\">",
"     87",
"    </a>",
"    ]. Parkinson's disease has not been associated with cocaine use.",
"   </p>",
"   <p>",
"    Cocaine use is associated with a variety of movement disorders, including stereotyped behaviors, acute dystonic reactions, choreoathetosis and akathisia (so-called \"crack dancers\"), buccolingual dyskinesias (\"twisted mouth\" or \"boca torcida\"), and exacerbation of Tourette's syndrome and tardive dyskinesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/49,78,88\">",
"     49,78,88",
"    </a>",
"    ]. Cocaine users are at increased risk of acute dystonic reactions from neuroleptic (antipsychotic) medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cardiovascular system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiopulmonary symptoms are the most frequent complaints in cocaine users who seek medical help, with chest pain the most frequent symptom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/90\">",
"     90",
"    </a>",
"    ]. Cocaine acutely increases heart rate, blood pressure, and systemic vascular resistance by increasing adrenergic activity in the heart, and indirectly via the CNS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. The increased myocardial oxygen demand, coupled with decreased coronary blood flow from vasospasm and vasoconstriction, can cause acute myocardial infarction, even in young persons without atherosclerosis. Cocaine use is a factor in about one-quarter of nonfatal heart attacks in persons younger than 45 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine use is not usually associated with chronic hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/93\">",
"     93",
"    </a>",
"    ], but appears to enhance the progression of renal disease in patients with hypertension (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Kidneys'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine use increases risk for cardiac arrhythmias and sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Chronic use is associated with left ventricular hypertrophy, cardiomyopathy, myocardial fibrosis, and myocarditis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Respiratory system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of cocaine on the respiratory system depend on the route of administration. Intranasal cocaine use (\"snorting\") may cause chronic rhinitis, perforation of the nasal septum, oropharyngeal ulcers, and osteolytic sinusitis, due to vasoconstriction and resulting ischemic necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/78,88\">",
"     78,88",
"    </a>",
"    ]. Anosmia is rare.",
"   </p>",
"   <p>",
"    Smoked cocaine use produces acute respiratory symptoms in up to half of users, including productive cough, shortness of breath, wheezing, chest pain, hemoptysis, and exacerbation of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/98\">",
"     98",
"    </a>",
"    ]. Rarer complications include pulmonary edema, pulmonary hemorrhage, pneumothorax, pneumomediastinum, and thermal airway injury. These effects are probably due to direct damage to the alveolar-capillary membrane by cocaine or inhaled microparticles, damage to the pulmonary vascular bed from vasoconstriction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interstitial disease. Chronic cocaine smokers generally have normal spirometry tests, but may have increased alveolar epithelial permeability and moderately decreased pulmonary diffusion capacity, even when asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34649?source=see_link\">",
"     \"Pulmonary complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Gastrointestinal system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine use by any route of administration reduces salivary secretions (xerostomia) and causes bruxism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/99\">",
"     99",
"    </a>",
"    ]. Cocaine reduces gastric motility and delays gastric emptying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/78\">",
"     78",
"    </a>",
"    ]. Cocaine-induced vasoconstriction and ischemia may result in gastrointestinal ulceration, infarction, perforation, and ischemic colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/78,88\">",
"     78,88",
"    </a>",
"    ]. Cocaine-associated ulcers are distributed primarily in the greater curvature and prepyloric region of the stomach, pyloric canal, but, similar to peptic ulcers, also occur in the first portion of the duodenum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no direct evidence that cocaine is hepatotoxic in humans, although it does cause liver damage in rodents. The hepatotoxic chemical norcocaine, a major metabolite of cocaine in rodents, is only a minor metabolite in humans (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Metabolism'",
"    </a>",
"    above). Liver abnormalities in cocaine users can almost always be accounted for by viral hepatitis from injection drug use, alcoholic liver disease, or other consequences of a drug-using lifestyle. Concurrent alcohol intake may sensitize hepatocytes to damage by cocaine, as well as generating the hepatotoxic metabolite cocaethylene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Kidneys",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine use can impair kidney function by a variety of mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Cocaine-induced rhabdomyolysis is a significant cause of acute renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6856?source=see_link\">",
"     \"Drug-induced myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .) Cocaine use by hypertensive patients enhances their decline in kidney function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/94\">",
"     94",
"    </a>",
"    ] and the progression from hypertensive nephrosclerosis to end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/95\">",
"     95",
"    </a>",
"    ]. While cocaine promotes atherosclerosis in renal vessels, cocaine-induced renal infarction is relatively rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Endocrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cocaine use activates the hypothalamic-pituitary-adrenal (HPA) axis, increasing levels of epinephrine, corticotropin-releasing hormone (CRH), ACTH, cortisol, and luteinizing hormone, and decreasing plasma prolactin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/88,105,106\">",
"     88,105,106",
"    </a>",
"    ]. Chronic cocaine users, however, usually have normal plasma levels of prolactin, testosterone, cortisol, luteinizing hormone, and thyroid hormones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine use is associated with a variety of pseudovasculitic lesions that may mimic rheumatologic syndromes such as Wegener's granulomatosis, necrotizing vasculitis, and Henoch Sch&ouml;nlein purpura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/107\">",
"     107",
"    </a>",
"    ]. Use of cocaine contaminated with levamisole (an anti-helminthic now approved in the US only for veterinary use) has been associated with cutaneous vasculitis or vasculopathy (",
"    <a class=\"graphic graphic_picture graphicRef74436 \" href=\"mobipreview.htm?15/28/15810\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H1117785#H1117785\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H810822#H810822\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Vasculitis due to levamisole-contaminated cocaine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Sexual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cocaine is often considered an aphrodisiac, it actually may impair sexual function, especially with chronic use, and may cause delayed or inhibited ejaculation in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/110-112\">",
"     110-112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Reproductive, fetal, and neonatal health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine may cause irregular menses in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/111,112\">",
"     111,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/54/8038?source=see_link\">",
"     Topical cocaine",
"    </a>",
"    is classified as pregnancy category C (risk cannot be ruled out because human studies are lacking) by the US Food and Drug Administration (FDA). Maternal cocaine use has been associated with vaginal bleeding, abruptio placenta, placenta previa, premature rupture of membranes, premature birth, decreased head circumference, low birth weight, and autonomic instability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. However, it is unclear to what extent these adverse effects are due to prenatal (in utero) cocaine exposure, rather than to other factors in the cocaine-using lifestyle, such as concomitant drug use (including alcohol, nicotine, and opiates), poor nutrition, and lack of prenatal care. Rodent and monkey studies, in which these confounding factors are excluded, show few direct adverse effects of prenatal exposure to cocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term effects of prenatal exposure to cocaine are also unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/116\">",
"     116",
"    </a>",
"    ]. Well-controlled, prospective studies of children born to cocaine-using mothers have not confirmed most earlier concerns regarding long-term cognitive impairment and behavioral problems.",
"   </p>",
"   <p>",
"    Cocaine appears in breast milk and may cause irritability, sleep disturbance, and tremors in the nursing infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SCREENING AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no broadly validated brief screening tests for cocaine abuse. Best studied are two tests modified from those used to screen for alcoholism: the 4-question CAGE and 2-question TICS (",
"    <a class=\"graphic graphic_table graphicRef53783 \" href=\"mobipreview.htm?0/5/85\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54106 \" href=\"mobipreview.htm?2/19/2363\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Both tests have sensitivities and specificities of 80 percent or greater in primary care settings for populations including women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/119\">",
"     119",
"    </a>",
"    ], pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/118\">",
"     118",
"    </a>",
"    ], the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/120\">",
"     120",
"    </a>",
"    ], and patients with HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Drug testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug testing detects cocaine use, but is not diagnostic of cocaine abuse, which implies adverse consequences from use. Conversely, a negative drug screen may only indicate lack of recent use. Cocaine and its metabolites can be measured in urine, blood, oral fluid, sweat, and hair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/41,122\">",
"     41,122",
"    </a>",
"    ]. The window of detection is shorter for cocaine than for its major metabolite, benzoylecgonine, and varies with the sensitivity of the assay method.",
"   </p>",
"   <p>",
"    Urine testing (which measures benzoylecgonine, not cocaine), including rapid point-of-care methods, is common in clinical settings because the sample can be collected non-invasively. It has a detection window of about two to three days after cocaine use, but may be positive up to two weeks after chronic heavy use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/123,124\">",
"     123,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood testing has a detection window of 12 hours for cocaine and 48 hours for benzoylecgonine. It is rarely used outside the setting of acute intoxication. Actual blood cocaine concentrations have little correlation with acute symptoms of cocaine intoxication in the emergency department setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral fluid testing has a detection window similar to that of blood, with the advantage of non-invasive collection and better patient acceptability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/37\">",
"     37",
"    </a>",
"    ]. Sweat testing (via patches worn on the skin) has a detection window of several weeks, but is useful only for prospective evaluation (ie, monitoring future drug intake). Results may be influenced by location of the skin patch and environmental exposure to cocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hair testing has the longest detection window (potentially years), but valid results require careful technique, and some questions remain unresolved. Results may be influenced by hair location,",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    differences in hair composition, prior hair treatments, and environmental exposure to cocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/126\">",
"     126",
"    </a>",
"    ]. Cocaine continues to be incorporated into hair for a few months after last use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of relatively inexpensive commercial assays are available for testing of urine and oral fluid, including disposable kits that allow on-site testing with results available within minutes. Results from such screening tests should be confirmed by a standard laboratory assay, especially in legal or workplace settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Definitions and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine abuse and dependence (sometimes termed addiction) are formal psychiatric diagnoses with explicit diagnostic criteria. These criteria, which apply to all psychoactive substances, are provided in the DSM-IV used in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/128\">",
"     128",
"    </a>",
"    ] and the International Classification of Diseases-10th revision (ICD-10) used elsewhere in the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/129\">",
"     129",
"    </a>",
"    ]. The core diagnostic concepts, as well as the actual criteria, are very similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/128\">",
"     128",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cocaine abuse is a \"maladaptive pattern\" of use that results in \"clinically significant impairment or distress\".",
"     </li>",
"     <li>",
"      Cocaine dependence is loss of control over use, as reflected in continued use despite adverse effects and more use than originally intended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical or pharmacological dependence (ie, tolerance or withdrawal) is not necessary for a diagnosis of psychological dependence. However, when present in a cocaine user, physical dependence is a powerful predictor of psychological dependence.",
"   </p>",
"   <p>",
"    The diagnosis of cocaine abuse or dependence is made on the basis of history, obtained primarily from the patient, but also, when available, from collateral sources (eg, family, friends, and medical records). Several validated psychiatric questionnaires and structured interviews (such as the SCID [Structured Clinical Interview for DSM-IV] and the DIS [Diagnostic Interview Schedule]) are available to diagnose cocaine abuse or dependence but require time and trained staff. Therefore, they are generally used only in specialized treatment or research settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Acute intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute intoxication is presented separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine withdrawal is treated by allowing the patient to sleep and eat ad lib in a supportive environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/130\">",
"     130",
"    </a>",
"    ]. No medication has been proven effective in treating the withdrawal syndrome, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    have been used on the theoretical basis that dopaminergic agents may ameliorate the hypothesized dopamine deficiency state of cocaine withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/131-133\">",
"     131-133",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    has been used to manage severe cocaine withdrawal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/134\">",
"     134",
"    </a>",
"    ] but can aggravate coronary vasoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/135\">",
"     135",
"    </a>",
"    ]. Hospitalization is rarely indicated on medical grounds, and has not been shown to improve the short-term outcome for cocaine addiction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/136,137\">",
"     136,137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A short-acting benzodiazepine such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    may be helpful in selected patients who develop severe agitation or sleep disturbance. Persistent (more than two to three weeks) depression or suicidal ideation may require antidepressant treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/130,138\">",
"     130,138",
"    </a>",
"    ]. The risk of relapse is high during the early withdrawal period, in part because drug craving is easily triggered by stress or encounters with drug-associated stimuli. Patients should be referred to an addiction treatment program for ongoing care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Treatment of addiction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment for cocaine addiction is psychosocial treatment. No medication is FDA labeled for this indication. Several organizations have issued practice guidelines for the treatment of cocaine addiction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/139-141\">",
"     139-141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of the initial psychiatric, medical, and psychosocial assessment (",
"    <a class=\"graphic graphic_table graphicRef75706 \" href=\"mobipreview.htm?19/56/20364\">",
"     table 4",
"    </a>",
"    ) is to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Determine the severity of the addiction problem",
"     </li>",
"     <li>",
"      Identify concurrent substance abuse (alcohol, opiates, or cannabis)",
"     </li>",
"     <li>",
"      Diagnose co-occurring psychiatric or medical disorders",
"     </li>",
"     <li>",
"      Identify strengths (eg, employment, supportive social network)",
"     </li>",
"     <li>",
"      Identify weaknesses (criminal behavior, poor social skills)",
"     </li>",
"     <li>",
"      Evaluate motivation for treatment",
"     </li>",
"     <li>",
"      Discuss treatment preferences",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The likelihood of a favorable outcome is enhanced by nonjudgmental empathy with the patient, quick engagement in the treatment program (ideally, within 24 hours), clear and realistic orientation to treatment goals and behavioral expectations, strict monitoring of drug use (eg, by frequent urine testing) with feedback to the patient, involvement of the patient's social network (to the extent possible), and attention to any concurrent medical, psychiatric, vocational, legal, or social problems. These requirements can be difficult to achieve in the typical primary care setting and are best met in a dedicated substance abuse treatment program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Treatment setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cocaine addiction treatment occurs in the outpatient setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/142\">",
"     142",
"    </a>",
"    ]. Inpatient or residential treatment may be warranted when required by medical or psychiatric comorbidity (eg, seizures, suicidal ideation); lack of patient access to a supportive, drug-free living environment; or history of past failures in intensive outpatient treatment. Explicit, operationalized criteria for selecting appropriate adult patient placement have been developed by the American Society for Addiction Medicine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/143\">",
"     143",
"    </a>",
"    ]. These criteria are based on multidimensional patient assessment generating placement along a continuum of care with varying lengths of treatment (",
"    <a class=\"graphic graphic_table graphicRef70400 \" href=\"mobipreview.htm?25/48/26379\">",
"     table 5",
"    </a>",
"    ). The criteria can be reliably implemented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/144\">",
"     144",
"    </a>",
"    ] and result in improved patient outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, patients with a shorter duration of addiction, fewer medical or psychiatric complications and co-morbidities, better psychosocial functioning (eg, employment, absence of anti-social behavior), and a supportive social network tend to have better outcomes, regardless of the treatment. However, adherence to treatment is by far the most important factor in predicting a successful outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Psychosocial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear evidence that any one psychosocial treatment is significantly better than another for most patients. Several psychotherapy or counseling modalities have been effective in clinical trials, eg motivational interviewing, psychodynamic (but not psychoanalysis), supportive, cognitive and behavioral therapies, including relapse prevention and contingency management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/146-148\">",
"     146-148",
"    </a>",
"    ]. A systematic review of psychosocial interventions found only small changes in rates of cocaine use for any intervention, with a suggestion that interventions incorporating contingency management were more effective and had lower drop out rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/149\">",
"     149",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=see_link&amp;anchor=H7#H7\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\", section on 'Motivational interviewing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=see_link&amp;anchor=H9#H9\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\", section on 'Cognitive behavioral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the modality used, more intensive treatment (ie, more frequent visits) and longer duration of treatment (minimum of three months) are associated with better outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/150,151\">",
"     150,151",
"    </a>",
"    ], especially during early abstinence. Long-term abstinence rates rarely approach 50 percent, except in some special patient populations. As an example, specialized programs treating addicted health care professionals have reported long-term abstinence rates exceeding 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/152\">",
"     152",
"    </a>",
"    ]. These better outcomes may relate to the strict monitoring, clearly defined and prompt consequences associated with relapse, good premorbid psychosocial functioning, and supportive social network associated with such patients.",
"   </p>",
"   <p>",
"    Involvement with peer self-help groups such as Cocaine Anonymous (modeled after Alcoholics Anonymous) improves treatment outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/153,154\">",
"     153,154",
"    </a>",
"    ]. Information about Cocaine Anonymous, including meeting locations, is available at",
"    <a class=\"external\" href=\"file://www.ca.org/\">",
"     www.ca.org",
"    </a>",
"    . Outcomes are also improved when addiction treatment is linked to primary medical care, and when appropriate psychiatric care and vocational rehabilitation are provided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/153,155\">",
"     153,155",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews of antidepressants, dopamine agonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    , pergolide), anticonvulsants, and antipsychotics (both first and second generation) have NOT demonstrated consistent effectiveness for treatment of cocaine dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/156-162\">",
"     156-162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several medications have shown promise in one or more phase II clinical trials, but none has shown consistent evidence of efficacy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/17/5397?source=see_link\">",
"       Disulfiram",
"      </a>",
"      (250 mg daily) was effective in four earlier trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/163\">",
"       163",
"      </a>",
"      ], but was not effective in the most recent two-site trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/164\">",
"       164",
"      </a>",
"      ]. In addition, safety concerns have been raised over its interactions with alcohol and cocaine in patients who do not abstain completely [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/163\">",
"       163",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"       Modafinil",
"      </a>",
"      (200-400 mg daily) decreased cocaine intake in one controlled clinical trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/165\">",
"       165",
"      </a>",
"      ], but not in a second larger trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/166\">",
"       166",
"      </a>",
"      ]. Post hoc analysis of the second trial suggested modafinil may reduce intake among patients without concurrent alcohol dependence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/166\">",
"       166",
"      </a>",
"      ]. Because modafinil has some stimulant-like properties and is subject to abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/167\">",
"       167",
"      </a>",
"      ], care should be taken to monitor for abuse or diversion.",
"     </li>",
"     <li>",
"      Some anti-convulsants such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      (200 mg daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/168\">",
"       168",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"       tiagabine",
"      </a>",
"      (12 mg or 24 mg daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/169\">",
"       169",
"      </a>",
"      ], and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"       vigabatrin",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/170\">",
"       170",
"      </a>",
"      ] have shown evidence of effectiveness in one or more phase II clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/169\">",
"       169",
"      </a>",
"      ]. Vigabatrin showed efficacy in only one of two controlled clinical trials. It received regulatory approval to be marketed in the US under restrictions because of retinal side effects.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      (1800 to 3200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      has not been found to decrease cocaine use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/169\">",
"       169",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preliminary findings from single trials suggest that the selective serotonin reuptake inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      (10 mg once daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/171\">",
"       171",
"      </a>",
"      ], and the serotonin (5-HT(3)) receptor antagonist",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      (4 mg twice daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/172\">",
"       172",
"      </a>",
"      ] may diminish cocaine intake in some patients.",
"     </li>",
"     <li>",
"      Some clinical trials suggest that agonist substitution treatment with long-acting oral stimulants (amphetamine, methamphetamine) (analogous to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      treatment of opioid dependence) may be effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/173,174\">",
"       173,174",
"      </a>",
"      ]. Care must be taken to avoid abuse or diversion, and there is the possibility of additive cardiovascular effects should the patient relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/175\">",
"       175",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients co-addicted to opiates as well as cocaine, and who are likely to benefit from opiate agonist maintenance treatment, may do well on high dose (16 to 32 mg daily)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/176\">",
"       176",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients co-addicted to alcohol as well as cocaine may show reduced drinking on high dose (100 mg daily)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/177-180\">",
"       177-180",
"      </a>",
"      ], but there is less evidence to suggest this regimen reduces cocaine use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/181\">",
"       181",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      (300 mg daily) when combined with a contingency management program (payment for negative urine samples) was also effective in co-addicted patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/182\">",
"       182",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other medications undergoing clinical trials include N-acetylcysteine (which alters brain glutamate activity) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/183,184\">",
"       183,184",
"      </a>",
"      ] and an anti-cocaine vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/185\">",
"       185",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pharmacological treatment is considered more effective when combined with psychosocial treatment, rather than given alone, although few clinical trials address this issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/186\">",
"     186",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative lack of effective conventional medical therapy for cocaine dependence has led to the investigation of alternative therapies. Neither acupuncture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/187-189\">",
"     187-189",
"    </a>",
"    ], nor herbal remedies such as ginkgo biloba [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/12/32970/abstract/190\">",
"     190",
"    </a>",
"    ] have been found to be effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/39/31346?source=see_link\">",
"       \"Patient information: Cocaine use disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cocaine use is most prevalent in North and South America, and increasingly in Western Europe, especially among urban men aged 15 to 35 years. It is the illegal drug most often associated with emergency department visits in the US. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Up to one in six persons who use cocaine will become dependent; abuse liability is greater with intravenous and smoked cocaine, compared to intranasal and oral use. Cocaine base has a low melting point and can be smoked; cocaine salt is water soluble and can be injected or absorbed across mucous membranes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors for use and abuse'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cocaine is largely metabolized to inactive hydrolytic products in the liver and plasma. Use of alcohol with cocaine produces a new metabolite, cocaethylene, which has actions similar to cocaine but a longer half-life. Concurrent alcohol use with cocaine may cause more severe and longer lasting toxic effects. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug testing detects the metabolite benzoylecgonine, which is usually detectable two to four days after the last cocaine use, although this can be up to 14 days after heavy, prolonged use. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Elimination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cocaine use increases energy and alertness, can produce euphoria, and decreases appetite and need for sleep. Adverse effects may include anxiety, irritability, paranoia, delusions, and hallucinations. These may be accompanied by tachycardia, diaphoresis, nausea, and pupil dilatation. There is poor correlation between cocaine plasma concentrations and toxicity. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Acute intoxication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Withdrawal symptoms from chronic cocaine use are predominantly psychological: depression, anxiety, anhedonia, cocaine craving, and increased sleep. Most symptoms are self limited and resolve within one to two weeks. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Withdrawal symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effects of cocaine on specific organ systems are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CNS: seizures, stroke, movement disorders",
"     </li>",
"     <li>",
"      Cardiovascular: myocardial infarction, arrhythmia, cardiomyopathy, myocarditis",
"     </li>",
"     <li>",
"      Respiratory: rhinitis and septal perforation (with intranasal use) cough, wheeze, chest pain (with smoked use)",
"     </li>",
"     <li>",
"      GI: xerostomia, gastric ulcers, ischemic colitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Effects on specific organ systems'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cocaine intoxication is treated with supportive care (ART: acceptance, reassurance, talkdown); benzodiazepines may be required to control severe agitation. Hospitalization may be indicated for psychotic symptoms or agitation that does not respond; symptoms that persist beyond a few days suggest an etiology other than cocaine use. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link\">",
"       \"Cocaine: Acute intoxication\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment for cocaine addiction occurs primarily in the outpatient setting, and involves psychosocial modalities. Rates for long-term abstinence are less than 50 percent. High-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      may be helpful for patients who are co-addicted to opiates;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/17/5397?source=see_link\">",
"       disulfiram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"       tiagabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      have shown some promise for cocaine abstinence. Peer group self-help programs (such as Cocaine Anonymous) improve outcomes. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Treatment of addiction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Karch, SB. A Brief History of Cocaine, 2nd ed, CRC Press, Boca Raton, FL 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/2\">",
"      Montoya ID, Chilcoat HD. Epidemiology of coca derivatives use in the Andean region: a tale of five countries. Subst Use Misuse 1996; 31:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/3\">",
"      Harper SJ, Jones NS. Cocaine: what role does it have in current ENT practice? A review of the current literature. J Laryngol Otol 2006; 120:808.",
"     </a>",
"    </li>",
"    <li>",
"     World Drug Report 2007. Report no. E.07.XI.5, United Nations Office on Drugs and Crime, Vienna, Austria 2007.",
"    </li>",
"    <li>",
"     The State of the Drugs Problem in Europe. European Monitoring Centre for Drugs and Drug Addiction, Luxembourg, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/6\">",
"      Degenhardt L, Chiu WT, Sampson N, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med 2008; 5:e141.",
"     </a>",
"    </li>",
"    <li>",
"     Results from the 2006 National Survey on Drug Use and Health: National Findings, Report no. SMA 07-4293, Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Rockville, MD 2005.",
"    </li>",
"    <li>",
"     Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network 2005 National Estimates of Drug-related Emergency Department Visits, DAWN Series D-29, DHHS Publication. No. (SMA) 074-4256, Rockville, MD 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/9\">",
"      Levin, FR, Hess, JM, Gorelick, DA, et al. Patterns of cocaine use among cocaine-dependent outpatients. Am J Addict 1993; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/10\">",
"      Myers MG, Rohsenow DJ, Monti PM, Dey A. Patterns of cocaine use among individuals in substance abuse treatment. Am J Drug Alcohol Abuse 1995; 21:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/11\">",
"      Kandel DB, Huang FY, Davies M. Comorbidity between patterns of substance use dependence and psychiatric syndromes. Drug Alcohol Depend 2001; 64:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/12\">",
"      Anthony, JC, Warner, LA, Kessler, RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Experimental and Clinical Psychopharmacology 1994; 23:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/13\">",
"      Gorelick DA. Progression of dependence in male cocaine addicts. Am J Drug Alcohol Abuse 1992; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/14\">",
"      Gossop M, Griffiths P, Powis B, Strang J. Cocaine: patterns of use, route of administration, and severity of dependence. Br J Psychiatry 1994; 164:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/15\">",
"      Woody GE, Cottler LB, Cacciola J. Severity of dependence: data from the DSM-IV field trials. Addiction 1993; 88:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/16\">",
"      Gorelick DA. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 1998; 42:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/17\">",
"      Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 1999; 13:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/18\">",
"      Nelson RA, Boyd SJ, Ziegelstein RC, et al. Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend 2006; 82:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/19\">",
"      Kendler KS, Myers J, Prescott CA. Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence. Arch Gen Psychiatry 2007; 64:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/20\">",
"      Uhl GR, Drgon T, Johnson C, et al. \"Higher order\" addiction molecular genetics: convergent data from genome-wide association in humans and mice. Biochem Pharmacol 2008; 75:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/21\">",
"      Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001; 39:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/22\">",
"      Howell LL, Kimmel HL. Monoamine transporters and psychostimulant addiction. Biochem Pharmacol 2008; 75:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/23\">",
"      Dackis CA, O'Brien CP. Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat 2001; 21:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/24\">",
"      Hatsukami DK, Fischman MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? JAMA 1996; 276:1580.",
"     </a>",
"    </li>",
"    <li>",
"     Karch, SB. The Pathology of Drug Abuse, 2nd ed, CRC Press, Boca Raton, FL 1996.",
"    </li>",
"    <li>",
"     U.S. Drug Enforcement Administration. Cocaine Price/Purity: Analysis of STRIDE Data. Washington, DC. 2008.",
"    </li>",
"    <li>",
"     Bono, JP. Criminalistics &mdash; Introduction to controlled substances. In: Drug Abuse Handbook, Karch, SB (Ed), CRC Press, Boca Raton, FL 1998. p. 1-75.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/28\">",
"      Shesser R, Jotte R, Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med 1991; 9:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/29\">",
"      Cone EJ, Yousefnejad D, Hillsgrove MJ, et al. Passive inhalation of cocaine. J Anal Toxicol 1995; 19:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/30\">",
"      Kavanagh KT, Maijub AG, Brown JR. Passive exposure to cocaine in medical personnel and its effect on urine drug screening tests. Otolaryngol Head Neck Surg 1992; 107:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/31\">",
"      Le SD, Taylor RW, Vidal D, et al. Occupational exposure to cocaine involving crime lab personnel. J Forensic Sci 1992; 37:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/32\">",
"      Mott SH, Packer RJ, Soldin SJ. Neurologic manifestations of cocaine exposure in childhood. Pediatrics 1994; 93:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/33\">",
"      Mirchandani HG, Mirchandani IH, Hellman F, et al. Passive inhalation of free-base cocaine ('crack') smoke by infants. Arch Pathol Lab Med 1991; 115:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/34\">",
"      Fowler JS, Volkow ND, Wang GJ, et al. [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol 2001; 28:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/35\">",
"      Musshoff F, Driever F, Lachenmeier K, et al. Results of hair analyses for drugs of abuse and comparison with self-reports and urine tests. Forensic Sci Int 2006; 156:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/36\">",
"      Follador MJ, Yonamine M, de Moraes Moreau RL, Silva OA. Detection of cocaine and cocaethylene in sweat by solid-phase microextraction and gas chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 811:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/37\">",
"      Pil K, Verstraete A. Current developments in drug testing in oral fluid. Ther Drug Monit 2008; 30:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/38\">",
"      American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/39\">",
"      Nice FJ, Snyder JL, Kotansky BC. Breastfeeding and over-the-counter medications. J Hum Lact 2000; 16:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/40\">",
"      Ostrea EM Jr. Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Curr Probl Pediatr 1999; 29:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/41\">",
"      Caplan YH, Goldberger BA. Alternative specimens for workplace drug testing. J Anal Toxicol 2001; 25:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/42\">",
"      Cone EJ. Pharmacokinetics and pharmacodynamics of cocaine. J Anal Toxicol 1995; 19:459.",
"     </a>",
"    </li>",
"    <li>",
"     Jenkins, AJ, Cone, EJ. Pharmacokinetics: drug absorption, distribution, and elimination. In: Drug Abuse Handbook, Karch, SB, (Ed), CRC Press, Boca Raton, FL 1998. p. 151.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/44\">",
"      Warner A, Norman AB. Mechanisms of cocaine hydrolysis and metabolism in vitro and in vivo: a clarification. Ther Drug Monit 2000; 22:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/45\">",
"      Gorelick, DA. Pharmacokinetic approaches to treatment of drug addiction. Expert Review of Clinical Pharmacology 2008; 1:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/46\">",
"      Cone EJ, Tsadik A, Oyler J, Darwin WD. Cocaine metabolism and urinary excretion after different routes of administration. Ther Drug Monit 1998; 20:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/47\">",
"      Pennings EJ, Leccese AP, Wolff FA. Effects of concurrent use of alcohol and cocaine. Addiction 2002; 97:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/48\">",
"      Baker J, Jatlow P, Pade P, et al. Acute cocaine responses following cocaethylene infusion. Am J Drug Alcohol Abuse 2007; 33:619.",
"     </a>",
"    </li>",
"    <li>",
"     Angrist, B. Clinical effects of central nervous system stimulants: A selective update. In: Brain Reward Systems and Abuse, Engel, J, Oreland, L, Ingvar, DH, et al (Eds). Raven Press, New York 1987. p. 109-27.",
"    </li>",
"    <li>",
"     Baselt, RC. Drug Effects on Psychomotor Performance. Biomedical Publications, Foster City, CA 2001.",
"    </li>",
"    <li>",
"     Fischman, MW, Foltin, RW. Cocaine self-administration research: implications for rational pharmacotherapy. In: Behavior, Pharmacology, and Clinical Applications, Higgins, ST, Katz, JL (Eds). Cocaine Abuse Academic Press, San Diego, CA 1998. p. 181-207.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/52\">",
"      Blaho K, Logan B, Winbery S, et al. Blood cocaine and metabolite concentrations, clinical findings, and outcome of patients presenting to an ED. Am J Emerg Med 2000; 18:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/53\">",
"      Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend 1997; 46:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/54\">",
"      Williamson S, Gossop M, Powis B, et al. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 1997; 44:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/55\">",
"      Rosse RB, Fay-McCarthy M, Collins JP Jr, et al. Transient compulsive foraging behavior associated with crack cocaine use. Am J Psychiatry 1993; 150:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/56\">",
"      Koob GF. Drug addiction: the yin and yang of hedonic homeostasis. Neuron 1996; 16:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/57\">",
"      Schenk S, Partridge B. Sensitization and tolerance in psychostimulant self-administration. Pharmacol Biochem Behav 1997; 57:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/58\">",
"      Kollins SH, Rush CR. Sensitization to the cardiovascular but not subject-rated effects of oral cocaine in humans. Biol Psychiatry 2002; 51:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/59\">",
"      Mendelson JH, Sholar M, Mello NK, et al. Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men. Neuropsychopharmacology 1998; 18:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/60\">",
"      Ward AS, Haney M, Fischman MW, Foltin RW. Binge cocaine self-administration in humans: intravenous cocaine. Psychopharmacology (Berl) 1997; 132:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/61\">",
"      Perez-Reyes M, White WR, McDonald SA, et al. Clinical effects of daily methamphetamine administration. Clin Neuropharmacol 1991; 14:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/62\">",
"      Rogers RD, Robbins TW. Investigating the neurocognitive deficits associated with chronic drug misuse. Curr Opin Neurobiol 2001; 11:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/63\">",
"      Friedman AS, Terras A, Zhu W, McCallum J. Depression, negative self-image, and suicidal attempts as effects of substance use and substance dependence. J Addict Dis 2004; 23:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/64\">",
"      Marzuk PM, Tardiff K, Leon AC, et al. Prevalence of cocaine use among residents of New York City who committed suicide during a one-year period. Am J Psychiatry 1992; 149:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/65\">",
"      Wilcox HC, Conner KR, Caine ED. Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies. Drug Alcohol Depend 2004; 76 Suppl:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/66\">",
"      Wines JD Jr, Saitz R, Horton NJ, et al. Suicidal behavior, drug use and depressive symptoms after detoxification: a 2-year prospective study. Drug Alcohol Depend 2004; 76 Suppl:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/67\">",
"      Roy A. Characteristics of cocaine-dependent patients who attempt suicide. Am J Psychiatry 2001; 158:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/68\">",
"      Sofuoglu M, Dudish-Poulsen S, Brown SB, Hatsukami DK. Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug Alcohol Depend 2003; 69:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/69\">",
"      Karmochkine M, Carrat F, Dos Santos O, et al. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepat 2006; 13:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/70\">",
"      Friedman H, Pross S, Klein TW. Addictive drugs and their relationship with infectious diseases. FEMS Immunol Med Microbiol 2006; 47:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/71\">",
"      Hill GE, Ogunnaike BO, Johnson ER. General anaesthesia for the cocaine abusing patient. Is it safe? Br J Anaesth 2006; 97:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/72\">",
"      Coffey SF, Dansky BS, Carrigan MH, Brady KT. Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. Drug Alcohol Depend 2000; 59:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/73\">",
"      Cottler LB, Shillington AM, Compton WM 3rd, et al. Subjective reports of withdrawal among cocaine users: recommendations for DSM-IV. Drug Alcohol Depend 1993; 33:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/74\">",
"      Lago JA, Kosten TR. Stimulant withdrawal. Addiction 1994; 89:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/75\">",
"      Khantzian EJ, McKenna GJ. Acute toxic and withdrawal reactions associated with drug use and abuse. Ann Intern Med 1979; 90:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/76\">",
"      Nademanee K, Gorelick DA, Josephson MA, et al. Myocardial ischemia during cocaine withdrawal. Ann Intern Med 1989; 111:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/77\">",
"      Reid MS, Flammino F, Howard B, et al. Topographic imaging of quantitative EEG in response to smoked cocaine self-administration in humans. Neuropsychopharmacology 2006; 31:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/78\">",
"      Boghdadi MS, Henning RJ. Cocaine: pathophysiology and clinical toxicology. Heart Lung 1997; 26:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/79\">",
"      Brust JC. Acute neurologic complications of drug and alcohol abuse. Neurol Clin 1998; 16:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/80\">",
"      Neiman J, Haapaniemi HM, Hillbom M. Neurological complications of drug abuse: pathophysiological mechanisms. Eur J Neurol 2000; 7:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/81\">",
"      Kilts CD, Schweitzer JB, Quinn CK, et al. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry 2001; 58:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/82\">",
"      Mena JC, Cuellar H, Vargas D, Riascos R. PET and SPECT in drug and substance abuse. Top Magn Reson Imaging 2005; 16:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/83\">",
"      Treadwell SD, Robinson TG. Cocaine use and stroke. Postgrad Med J 2007; 83:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/84\">",
"      Westover AN, McBride S, Haley RW. Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry 2007; 64:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/85\">",
"      Rojas R, Riascos R, Vargas D, et al. Neuroimaging in drug and substance abuse part I: cocaine, cannabis, and ecstasy. Top Magn Reson Imaging 2005; 16:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/86\">",
"      Magalhaes AC. Functional magnetic resonance and spectroscopy in drug and substance abuse. Top Magn Reson Imaging 2005; 16:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/87\">",
"      Little KY, Ramssen E, Welchko R, et al. Decreased brain dopamine cell numbers in human cocaine users. Psychiatry Res 2009; 168:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/88\">",
"      Warner EA. Cocaine abuse. Ann Intern Med 1993; 119:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/89\">",
"      van Harten PN, van Trier JC, Horwitz EH, et al. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry 1998; 59:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/90\">",
"      McCord J, Jneid H, Hollander JE, et al. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation 2008; 117:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/91\">",
"      Afonso L, Mohammad T, Thatai D. Crack whips the heart: a review of the cardiovascular toxicity of cocaine. Am J Cardiol 2007; 100:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/92\">",
"      Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation 2001; 103:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/93\">",
"      Brecklin CS, Gopaniuk-Folga A, Kravetz T, et al. Prevalence of hypertension in chronic cocaine users. Am J Hypertens 1998; 11:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/94\">",
"      Vupputuri S, Batuman V, Muntner P, et al. The risk for mild kidney function decline associated with illicit drug use among hypertensive men. Am J Kidney Dis 2004; 43:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/95\">",
"      Norris KC, Thornhill-Joynes M, Robinson C, et al. Cocaine use, hypertension, and end-stage renal disease. Am J Kidney Dis 2001; 38:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/96\">",
"      Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/97\">",
"      Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart 2000; 83:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/98\">",
"      Tashkin DP. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med 2001; 7:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/99\">",
"      Pallasch TJ, Joseph CE. Oral manifestations of drug abuse. J Psychoactive Drugs 1987; 19:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/100\">",
"      Ponsoda X, Bort R, Jover R, et al. Increased toxicity of cocaine on human hepatocytes induced by ethanol: role of GSH. Biochem Pharmacol 1999; 58:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/101\">",
"      Gitman MD, Singhal PC. Cocaine-induced renal disease. Expert Opin Drug Saf 2004; 3:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/102\">",
"      Jaffe JA, Kimmel PL. Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol 2006; 1:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/103\">",
"      Fernandez WG, Hung O, Bruno GR, et al. Factors predictive of acute renal failure and need for hemodialysis among ED patients with rhabdomyolysis. Am J Emerg Med 2005; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/104\">",
"      Bemanian S, Motallebi M, Nosrati SM. Cocaine-induced renal infarction: report of a case and review of the literature. BMC Nephrol 2005; 6:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/105\">",
"      Mello NK, Mendelson JH. Cocaine's effects on neuroendocrine systems: clinical and preclinical studies. Pharmacol Biochem Behav 1997; 57:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/106\">",
"      Warner EA, Greene GS, Buchsbaum MS, et al. Diabetic ketoacidosis associated with cocaine use. Arch Intern Med 1998; 158:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/107\">",
"      Bhinder SK, Majithia V. Cocaine use and its rheumatic manifestations: a case report and discussion. Clin Rheumatol 2007; 26:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/108\">",
"      Gross RL, Brucker J, Bahce-Altuntas A, et al. A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clin Rheumatol 2011; 30:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/109\">",
"      Chung C, Tumeh PC, Birnbaum R, et al. Characteristic purpura of the ears, vasculitis, and neutropenia--a potential public health epidemic associated with levamisole-adulterated cocaine. J Am Acad Dermatol 2011; 65:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/110\">",
"      Macdonald, PT, Waldorf, D, Reinarman, C, Murphy, S. Heavy cocaine use and sexual behavior. J Drug Issues 1988; 18:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/111\">",
"      Palha AP, Esteves M. Drugs of abuse and sexual functioning. Adv Psychosom Med 2008; 29:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/112\">",
"      Carey JC. Pharmacological effects on sexual function. Obstet Gynecol Clin North Am 2006; 33:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/113\">",
"      Chiriboga CA. Fetal alcohol and drug effects. Neurologist 2003; 9:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/114\">",
"      Kuczkowski KM. The effects of drug abuse on pregnancy. Curr Opin Obstet Gynecol 2007; 19:578.",
"     </a>",
"    </li>",
"    <li>",
"     Schama, KF, Howell, LL, Byrd, LD. Prenatal exposure to cocaine. In: Cocaine Abuse: Behavior, Pharmacology, and Clinical Applications, Higgins, ST, Katz, JL, (Eds), Academic Press, San Diego, CA 1998. p. 159-79.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/116\">",
"      Williams JH, Ross L. Consequences of prenatal toxin exposure for mental health in children and adolescents: a systematic review. Eur Child Adolesc Psychiatry 2007; 16:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/117\">",
"      Brown RL, Leonard T, Saunders LA, Papasouliotis O. A two-item conjoint screen for alcohol and other drug problems. J Am Board Fam Pract 2001; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/118\">",
"      Midanik LT, Zahnd EG, Klein D. Alcohol and drug CAGE screeners for pregnant, low-income women: the California Perinatal Needs Assessment. Alcohol Clin Exp Res 1998; 22:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/119\">",
"      Davis TM, Bush KR, Kivlahan DR, et al. Screening for substance abuse and psychiatric disorders among women patients in a VA Health Care System. Psychiatr Serv 2003; 54:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/120\">",
"      Hinkin CH, Castellon SA, Dickson-Fuhrman E, et al. Screening for drug and alcohol abuse among older adults using a modified version of the CAGE. Am J Addict 2001; 10:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/121\">",
"      Pence BW, Gaynes BN, Whetten K, et al. Validation of a brief screening instrument for substance abuse and mental illness in HIV-positive patients. J Acquir Immune Defic Syndr 2005; 40:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/122\">",
"      Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit 2004; 26:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/123\">",
"      Preston KL, Epstein DH, Cone EJ, et al. Urinary elimination of cocaine metabolites in chronic cocaine users during cessation. J Anal Toxicol 2002; 26:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/124\">",
"      Cone EJ, Weddington WW Jr. Prolonged occurrence of cocaine in human saliva and urine after chronic use. J Anal Toxicol 1989; 13:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/125\">",
"      Uemura N, Nath RP, Harkey MR, et al. Cocaine levels in sweat collection patches vary by location of patch placement and decline over time. J Anal Toxicol 2004; 28:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/126\">",
"      Gambelunghe C, Rossi R, Ferranti C, et al. Hair analysis by GC/MS/MS to verify abuse of drugs. J Appl Toxicol 2005; 25:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/127\">",
"      Felli M, Martello S, Marsili R, Chiarotti M. Disappearance of cocaine from human hair after abstinence. Forensic Sci Int 2005; 154:96.",
"     </a>",
"    </li>",
"    <li>",
"     Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text revision. American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     The ICD-10 Classification of Mental and Behavioral Disorders. Clinical Descriptions and Diagnostic Guidelines. World Heath Organization, Geneva 1992.",
"    </li>",
"    <li>",
"     Schuckit, MA. Drug and Alcohol Abuse. A Clinical Guide to Diagnosis and Treatment, 6th ed, Springer, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/131\">",
"      Gill, K, Gillespie, HK, Hollister, LE. Dopamine depletion hypothesis of cocaine dependence: A test. Human Psychopharmacology 1991; 6:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/132\">",
"      Satel SL, Price LH, Palumbo JM, et al. Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry 1991; 148:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/133\">",
"      Volkow ND, Hitzemann R, Wang GJ, et al. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 1992; 11:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/134\">",
"      Kampman KM, Volpicelli JR, Mulvaney F, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2001; 63:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/135\">",
"      Lange RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990; 112:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/136\">",
"      Mulvaney FD, Alterman AI, Boardman CR, Kampman K. Cocaine abstinence symptomatology and treatment attrition. J Subst Abuse Treat 1999; 16:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/137\">",
"      Rosenblum A, Foote J, Magura S, et al. Follow-up of inpatient cocaine withdrawal for cocaine-using methadone patients. J Subst Abuse Treat 1996; 13:467.",
"     </a>",
"    </li>",
"    <li>",
"     Weiss, RD, Greenfield, SF, Mirin, SM. Intoxication and withdrawal syndromes. In: Manual of Psychiatric Emergencies, Hyman, SE, (Ed), Little, Brown &amp; Co, Boston, MA 1994. p. 279-93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/139\">",
"      American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders, 2nd edition. Am J Psychiatry 2006; 163 Suppl:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/140\">",
"      Lingford-Hughes AR, Welch S, Nutt DJ, British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2004; 18:293.",
"     </a>",
"    </li>",
"    <li>",
"     Rawson, RA (ed). Treatment for Stimulant Use Disorders (TIPS #33). Center for Substance Abuse Treatment, Rockville, MD 1999.",
"    </li>",
"    <li>",
"     Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS): 2003, Discharge from Substance Abuse Treatment Services. DASIS Series: S-30, DHHS Publication No. (SMA) 06-4139, Rockville, MD 2006. Available online at: www.oas.samhsa.gov (Accessed August 4, 2006).",
"    </li>",
"    <li>",
"     Mee-Lee, D, Shulman, GD, Fishman, M, et al. ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders. 2nd edition revised. American Society of Addiction Medicine, Chevy Chase, MD 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/144\">",
"      Baker SL, Gastfriend DR. Reliability of multidimensional substance abuse treatment matching: implementing the ASAM Patient Placement Criteria. J Addict Dis 2003; 22 Suppl 1:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/145\">",
"      Gastfriend DR, Rubin A, Sharon E, et al. New constructs and assessments for relapse and continued use potential in the ASAM Patient Placement Criteria. J Addict Dis 2003; 22 Suppl 1:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/146\">",
"      Carroll KM. Recent advances in the psychotherapy of addictive disorders. Curr Psychiatry Rep 2005; 7:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/147\">",
"      Crits-Christoph P, Siqueland L, Blaine J, et al. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry 1999; 56:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/148\">",
"      Woody GE. Research findings on psychotherapy of addictive disorders. Am J Addict 2003; 12 Suppl 2:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/149\">",
"      Knapp WP, Soares BG, Farrel M, Lima MS. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst Rev 2007; :CD003023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/150\">",
"      Simpson DD, Joe GW, Fletcher BW, et al. A national evaluation of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 1999; 56:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/151\">",
"      Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003; 98:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/152\">",
"      Domino KB, Hornbein TF, Polissar NL, et al. Risk factors for relapse in health care professionals with substance use disorders. JAMA 2005; 293:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/153\">",
"      Carroll KM. Implications of recent research for program quality in cocaine dependence treatment. Subst Use Misuse 2000; 35:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/154\">",
"      Weiss RD, Griffin ML, Gallop RJ, et al. The effect of 12-step self-help group attendance and participation on drug use outcomes among cocaine-dependent patients. Drug Alcohol Depend 2005; 77:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/155\">",
"      Saitz R, Horton NJ, Larson MJ, et al. Primary medical care and reductions in addiction severity: a prospective cohort study. Addiction 2005; 100:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/156\">",
"      Hamilton JD, Nguyen QX, Gerber RM, Rubio NB. Olanzapine in cocaine dependence: a double-blind, placebo-controlled trial. Am J Addict 2009; 18:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/157\">",
"      Loebl T, Angarita GA, Pachas GN, et al. A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. J Clin Psychiatry 2008; 69:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/158\">",
"      Lima AR, Lima MS, Soares BG, Farrell M. Carbamazepine for cocaine dependence. Cochrane Database Syst Rev 2002; :CD002023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/159\">",
"      Amato L, Minozzi S, Pani PP, Davoli M. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev 2007; :CD006306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/160\">",
"      Minozzi S, Amato L, Davoli M, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev 2008; :CD006754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/161\">",
"      Amato L, Minozzi S, Pani PP, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev 2011; :CD003352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/162\">",
"      Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database Syst Rev 2011; :CD002950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/163\">",
"      Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/164\">",
"      Oliveto A, Poling J, Mancino MJ, et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend 2011; 113:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/165\">",
"      Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/166\">",
"      Anderson AL, Reid MS, Li SH, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009; 104:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/167\">",
"      Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009; 301:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/168\">",
"      Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/169\">",
"      Gonz&aacute;lez G, Desai R, Sofuoglu M, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend 2007; 87:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/170\">",
"      Brodie JD, Case BG, Figueroa E, et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009; 166:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/171\">",
"      Moeller FG, Schmitz JM, Steinberg JL, et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 2007; 33:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/172\">",
"      Johnson BA, Roache JD, Ait-Daoud N, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend 2006; 84:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/173\">",
"      Mooney ME, Herin DV, Schmitz JM, et al. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2009; 101:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/174\">",
"      Shearer J. The principles of agonist pharmacotherapy for psychostimulant dependence. Drug Alcohol Rev 2008; 27:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/175\">",
"      Rush CR, Stoops WW, Hays LR. Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend 2009; 99:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/176\">",
"      Montoya ID, Gorelick DA, Preston KL, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004; 75:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/177\">",
"      Schmitz JM, Lindsay JA, Green CE, et al. High-dose naltrexone therapy for cocaine-alcohol dependence. Am J Addict 2009; 18:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/178\">",
"      Pettinati HM, Kampman KM, Lynch KG, et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav 2008; 33:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/179\">",
"      Schmitz JM, Stotts AL, Sayre SL, et al. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am J Addict 2004; 13:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/180\">",
"      Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berl) 1998; 139:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/181\">",
"      Schmitz JM, Stotts AL, Rhoades HM, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 2001; 26:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/182\">",
"      Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006; 63:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/183\">",
"      Mardikian PN, LaRowe SD, Hedden S, et al. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/184\">",
"      LaRowe SD, Myrick H, Hedden S, et al. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 2007; 164:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/185\">",
"      Martell BA, Orson FM, Poling J, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009; 66:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/186\">",
"      Montoya ID, Schroeder JR, Preston KL, et al. Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat 2005; 28:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/187\">",
"      Margolin A, Kleber HD, Avants SK, et al. Acupuncture for the treatment of cocaine addiction: a randomized controlled trial. JAMA 2002; 287:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/188\">",
"      Gates S, Smith LA, Foxcroft DR. Auricular acupuncture for cocaine dependence. Cochrane Database Syst Rev 2006; :CD005192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/189\">",
"      Mills EJ, Wu P, Gagnier J, Ebbert JO. Efficacy of acupuncture for cocaine dependence: a systematic review &amp; meta-analysis. Harm Reduct J 2005; 2:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/12/32970/abstract/190\">",
"      Kampman K, Majewska MD, Tourian K, et al. A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. Addict Behav 2003; 28:437.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7802 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32970=[""].join("\n");
var outline_f32_12_32970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patterns of use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors for use and abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Onset of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Duration of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Elimination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL EFFECTS OF COCAINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chronic use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Withdrawal symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EFFECTS ON SPECIFIC ORGAN SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cardiovascular system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Respiratory system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Gastrointestinal system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Kidneys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Endocrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Reproductive, fetal, and neonatal health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SCREENING AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Drug testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Definitions and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Treatment of addiction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Treatment setting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Psychosocial treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7802\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7802|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/28/15810\" title=\"picture 1\">",
"      Cocaine purpura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7802|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/58/14252\" title=\"table 1\">",
"      Common street names cocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/5/85\" title=\"table 2\">",
"      Two Item Conjoint Screen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/19/2363\" title=\"table 3\">",
"      CAGE questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/56/20364\" title=\"table 4\">",
"      Initial assessment cocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/48/26379\" title=\"table 5\">",
"      ASM criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=related_link\">",
"      Evaluation of adults with cutaneous lesions of vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/39/31346?source=related_link\">",
"      Patient information: Cocaine use disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34649?source=related_link\">",
"      Pulmonary complications of cocaine abuse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_12_32971="Side chains amp amox ceph";
var content_f32_12_32971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cephalosporins and penicillins with identical side chains",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Amoxicillin:",
"            <br/>",
"            Has side chains that are identical to:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefadroxil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefprozil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefatrizine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Ampicillin:",
"            <br/>",
"            Has side chains that are identical to:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefaclor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cephalexin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cephradine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cephaloglycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Loracarbef (a carbacephem)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    List of cephalosporins that share identical R1-group side chains with R-group side chain of amoxicillin and ampicillin. Note that clinical cross-reactivity has only been reported among beta-lactams with",
"    <strong>",
"     identical",
"    </strong>",
"    side chains and not among those with similar side chains.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32971=[""].join("\n");
var outline_f32_12_32971=null;
var title_f32_12_32972="MEN2 timing thyroidectomy";
var content_f32_12_32972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F71392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F71392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mutated RET codon-based genotype-phenotype correlation: Recommended age for prophylactic thyroidectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Level*",
"       </td>",
"       <td class=\"subtitle1\">",
"        RET genotype (mutation in codon)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended timing of surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D",
"       </td>",
"       <td>",
"        883, 918, 804&bull;",
"       </td>",
"       <td>",
"        Before age&nbsp;one year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        634",
"       </td>",
"       <td>",
"        Two&nbsp;to&nbsp;four years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B",
"       </td>",
"       <td>",
"        609, 611, 618, 620, 630, 804&Delta;",
"       </td>",
"       <td>",
"        Before age&nbsp;six years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        533, 649, 666, 768, 790, 791, 804&loz;, 891, 912",
"       </td>",
"       <td>",
"        Before age 10 years or after abnormal stimulation test",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Risk of MTC development in MEN2 depends on mutated RET codon.",
"    <div class=\"footnotes\">",
"     * Level of malignancy (risk) from high to low (D &rarr; A).",
"     <br>",
"      &bull; Tandem mutation (804-805, 804-806, 804-904).",
"      <br>",
"       &Delta; Tandem mutation (804-778).",
"       <br>",
"        &loz; Single mutation.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     1. Lips C. Approach to therapy in multiple endocrine neoplasia type 2. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA 2012.",
"     <br>",
"      2. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658.",
"      <br>",
"       3. Machens A, Ukkat J, Brauckhoff M, et al. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 2005; 257:50.",
"       <br>",
"        4. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005; 353:1105.",
"        <br>",
"         5. Machens A, Dralle H. Genotype-Phenotype Based Surgical Concept of Hereditary Medullary Thyroid Carcinoma. World J Surg 2007; 31:957.",
"         <br>",
"          6. Clark OH, Ajani J, Benson AB, 3rd, et al. Neuroendocrine tumors. J Natl Compr Canc Netw 2006; 4:102.",
"          <br>",
"           7. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565.",
"           <br>",
"            8. Gimm O, Marsh DJ, Andrew SD, et al. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in MEN 2B without codon 918 mutation. J Clin Endocrinol Metab 1997; 82:3902.",
"            <br>",
"             9. Smith DP, Houghton C, Ponder BA. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 1997; 15:1213.",
"             <br>",
"              10. Romei C, Mariotti S, Fugazzola L, et al. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol 2010; 163:301.",
"              <br>",
"               11. Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med 2011; 13:755.",
"               <br>",
"                12. Raue F, Frank-Raue K. Update multiple endocrine neoplasia type 2. Fam Cancer 2010; 9:449.",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32972=[""].join("\n");
var outline_f32_12_32972=null;
var title_f32_12_32973="Drug and toxin related temperature change";
var content_f32_12_32973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug- and toxin-induced temperature abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hyperthermia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Increased heat production",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Muscular hyperactivity/rigidity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3_start\">",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Phenylpropanolamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Ephedrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Cathinones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Anticholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Drug withdrawal states",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3_start\">",
"            Central hallucinogens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Phencyclidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Lysergic acid diethylamide (LSD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Designer amphetamines (MDMA, MDEA)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Synthetic cannabinoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3_start\">",
"            Drugs causing recurrent seizures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Isoniazid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Strychnine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Neuroleptic malignant syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Serotonin syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            MAO inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Malignant hyperthermia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Impaired heat dissipation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Impaired sweating",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3_start\">",
"            Anticholinergic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Phenothiazines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist3\">",
"            Tricyclic antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Increased metabolic rate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Uncoupled oxidative phosphorylation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Salicylates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Dinitrophenol, pentachlorophenol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thyroid hormone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Hypersensitivity reactions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Metal fume fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Polymer fume fever",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypothermia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Opioids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sedative-hypnotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Benzodiazepines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Barbiturates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Alcohols",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sympatholytics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Beta blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Clonidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Alpha-adrenergic antagonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoglycemic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antipsychotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            General anesthetic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drugs which cause flaccid coma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32973=[""].join("\n");
var outline_f32_12_32973=null;
var title_f32_12_32974="Bone sarcoma incidence SEER";
var content_f32_12_32974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Bone cancer age-specific incidence rates by histology, all races, both sexes, SEER 1976-84 and 1986-94 combined",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 375px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Malignant bone tumors. Bleyer A, O'Leary M, Barr R, Ries LAG (eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32974=[""].join("\n");
var outline_f32_12_32974=null;
var title_f32_12_32975="Cross cradle position PI";
var content_f32_12_32975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Cross-cradle position for breastfeeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cross-cradle hold can also be done while the mother sits in a chair. To feed from the left breast, the infant's head and body are supported by the mother's right hand and forearm. Some women use a pillow to support this arm. The baby's stomach should be flat against the mother's chest and the baby's head should be in line with the body (not turned). The mother's free hand (the left hand in this example) supports and guides the breast to the infant's wide open mouth. The thumb on the free hand may be placed on top of the areola and the breast supported with the cupped fingers. Care should be taken to position the hand away from the nipple so that the thumb and fingers do not interfere with latching.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_12_32975=[""].join("\n");
var outline_f32_12_32975=null;
